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Abstract: Small metabolites and peptides in 17 snake venoms (Elapidae, Viperinae, and Crotalinae),
were quantified using liquid chromatography-mass spectrometry. Each venom contains >900 metabolites
and peptides. Many small organic compounds are present at levels that are probably significant
in prey envenomation, given that their known pharmacologies are consistent with snake
envenomation strategies. Metabolites included purine nucleosides and their bases, neurotransmitters,
neuromodulators, guanidino compounds, carboxylic acids, amines, mono- and disaccharides,
and amino acids. Peptides of 2–15 amino acids are also present in significant quantities, particularly
in crotaline and viperine venoms. Some constituents are specific to individual taxa, while others
are broadly distributed. Some of the latter appear to support high anabolic activity in the gland,
rather than having toxic functions. Overall, the most abundant organic metabolite was citric acid,
owing to its predominance in viperine and crotaline venoms, where it chelates divalent cations
to prevent venom degradation by venom metalloproteases and damage to glandular tissue by
phospholipases. However, in terms of their concentrations in individual venoms, adenosine, adenine,
were most abundant, owing to their high titers in Dendroaspis polylepis venom, although hypoxanthine,
guanosine, inosine, and guanine all numbered among the 50 most abundant organic constituents.
A purine not previously reported in venoms, ethyl adenosine carboxylate, was discovered in
D. polylepis venom, where it probably contributes to the profound hypotension caused by this
venom. Acetylcholine was present in significant quantities only in this highly excitotoxic venom,
while 4-guanidinobutyric acid and 5-guanidino-2-oxopentanoic acid were present in all venoms.
Keywords: snake venoms; metabolites; peptides; purine nucleosides and bases; neurotransmitters;
neuromodulators; guanidinium compounds; carboxylic acids; amines; mono- and disaccharides;
amino acids
Key Contribution: This paper presents the first comprehensive analysis of small metabolites in snake
venoms and shows that some of these undoubtedly contribute to prey immobilization. Many novel
di-, tri-, and tetrapeptide sequences have been determined.
1. Introduction
In contrast to insect, arachnid, and anuran venoms, snake venom chemistry is dominated by
proteins. As a result, relatively little attention has been paid to small organic constituents thereof.
Ganguly and Malkana [1] detected cholesterol and lecithin in cobra venom, and Devi [2] claimed that
glycerophosphate was present in cobra, viper, and pitviper venoms. Monosaccharides and free amino
acids have also been reported, but no role in envenomation for these non-proteinaceous components
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has ever been suggested. Bieber [3] published the last thorough review of non-proteinaceous snake
venom constituents.
Aird [4] proposed that the purine nucleosides adenosine, inosine, and guanosine, documented
in various venoms [5–11], actually occupy a central position in the envenomation strategies of all
venomous snakes, whether as venom constituents, or when released from prey tissues by venom
proteins and the biochemical cascade they unleash. Later Aird [12,13] documented the purine levels
in both snake and helodermatid venoms, confirming that some ophidian venoms comprise as much
as 8.7% nucleosides by mass, exceeding the levels of many proteinaceous toxins and lending further
credence to his earlier hypothesis about their strategic importance.
Recently, after deproteinating snake venom samples to serve as controls in another study, we were
surprised to discover that the small metabolite content of snake venoms is vastly richer than we
imagined. While it might have been reasonable to expect trace levels of a broad array of compounds,
due to death and replacement of venom gland cells, many of these compounds are 3–6 orders of
magnitude more abundant than such anticipated background levels. Accordingly, we identified
and semi-quantified small metabolites and peptides in 17 snake venoms representing the families
Elapidae (8), Viperinae (2), and Crotalinae (7). Elapid venoms include three individual samples
from Micrurus surinamensis, in order to assess levels of individual variation; thus, 15 snake taxa
were examined.
The diversity of small metabolites seen in these venoms greatly exceeds what has been reported
previously. While many of the more abundant compounds have well-known pharmacologies, some,
like adenosine, can exert opposing effects, depending upon their tissue concentrations. Like the
proteinaceous constituents, titers of these metabolites vary between individuals and between taxa.
Undoubtedly, some of them act synergistically with proteinaceous venom components to achieve rapid
immobilization of prey.
2. Results and Discussion
2.1. Compounds Isolated from Snake Venoms
Deproteinated samples of 17 snake venoms (Supplementary Table S1) were analyzed by liquid
chromatography-mass spectrometry, with simultaneous detection of positive and negative ions
(Figure 1). Both positive and negative ions were combined into a master table containing all 17 datasets.
Ions were identified on the basis of mass, chromatographic retention time, and fragmentation pattern.
Each venom contained roughly 900 LC-MS peaks containing small organic molecules and peptides
(<2 kDa). Not all of these peaks represent unique compounds. Some metabolites interact with
others during LC, with the result that the same compound occasionally elutes in more than one
location. In addition to these duplicate peaks, highly concentrated metabolites, such as adenosine,
citric acid, and guanosine, sometimes produced fragments. Still others, such as a couple of tripeptides,
were identified not only as monomers, but produced a secondary dimeric peak. Data from these
“duplicate peaks” were manually combined. It is safe to say that each venom contained in excess
of 850 small organic molecules and peptides. Unquestionably, many more are present at trace
levels. For example, we found xanthosine in preliminary experiments, but it was not detected
automatically in the final dataset. A manual search in the venom of Bungarus multicinctus, where it
had previously been most abundant, revealed that it was indeed present, but at levels only slightly
above background noise. Accordingly, we have tried to be conservative here. All but one of the 50
most abundant metabolites (Figure 2, Supplementary Table S1) were positively identified, or at least,
well characterized. Identifications beyond the top 50 compounds are considered tentative for small
metabolites. Peptide sequences provided are confirmed.
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Figure 1. Total ion chromatograms of negative and positive ions of metabolites and peptides from 
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Figure 1. Total ion chromatograms of negative and positive ions of metabolites and peptides from
Agkistrodon piscivorus leucostoma venom. The negative ion peak that dwarfs all others is citric acid.
Assuming no metabolite loss during deproteination, the metabolites and peptides separated here
represent the small molecule component of ~69 µg of crude venom. Metabolites were separated on a
SeQuant ZIC-pHILIC HPLC 2.1 × 150 mm column, flow rate 120 µL/min, using acetonitrile as solvent
A, and 10 mM ammonium carbonate, 0.1% ammonium hydroxide in water as solvent B. Separation
was done in HILIC mode, with a linear gradient from 20% to 80% solvent B in 30 min, followed by a
wash for 20 min with 20% acetonitrile, 0.5 M sodium chloride in water (solvent C) and, finally, column
re-equilibration with starting conditions for 15 min.
Quantities of these small molecules present in each venom differed by orders of magnitude,
within and across species, a pattern mimicking that of snake venom proteins [14–16] (Figure 2,
Supplementary Table S1). Based upon their adjusted areas (the sum of positive and negative ion
peak areas for all venoms), the most abundant small venom constituents included carboxylic acids
(some of which possessed guanidino groups), purine nucleosides and their bases, neurotransmitters
and neuromodulators, amines (mostly tertiary amines), amino acids, and peptides ranging from 2 to
15 amino acids.
Metabolites identified are discussed below by class and within each class they are presented
in order of their decreasing maximum abundance in the venoms examined. That sequence reflects
their possible strategic importance in the venoms in which they achieved their highest concentrations,
and not necessarily their mean abundance across all venoms examined.
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Figure 2. Heat map of the 50 most abundant etabolites and eptides found in 17 snake venoms,
arranged in decreasing order of the maximum concentrations found among the species examined.
Compound abundances represent the log10 of peak intensities of positive and negative ions combined,
after subtraction of respective baselines. Logarithmic representations have the effect of compressing
apparent differences, so these veno s are compositionally much more divergent than can be shown
graphically. Taxonom names: B u, Bungarus multicinctus; Dp, Dendroas is olylepis; Msp, Micrurus
spixii; Ms1–3, Micrurus surinamensis, 3 individuals; Nk, Naja kaouthia; Oh, Ophiophagus hannah;
Cc, Cerastes cerastes; Ds, Daboia siamensis; Apl, Agkistrodon piscivorus leucostoma; Bmo, Bothrops moojeni;
Cdt, Crotalus durissus terrificus; Cvv, Crotalus viridis viridis; Oo, Ovophis okinavensis; Pe, Protobothrops
elegans; Pf, Protobothrops flavoviridis.
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2.2. Carboxylic Acids That Chelate Divalent Cations
2.2.1. Citric Acid
Citric acid was present in in all venoms and was the first-ranked metabolite overall
(Figures 3 and 4, Supplementary Table S1). Its concentration was 2–3 orders of magnitude greater in
viperine and crotaline venoms than in elapid venoms. Citrate was first discovered in snake venoms in
the laboratory of Ivan I. Kaiser [17,18]. Francis et al. [18] found citrate concentrations ranging from 95
to 150 mM in viperine venoms, from 63 to 142 mM in crotalines, and from 17 to 163 mM in elapids.
They found that in Bothrops asper venom, Ca2+ concentrations ranged from 2.5 to 3.6 mM. At those Ca2+
concentrations, a phospholipase A2 from Bothrops asper venom was completely inhibited by only 20 mM
citrate. They further reported that Crotalus adamanteus 5′-nucleotidase and phosphodiesterase were
inhibited 100% and 75%, respectively, by 100 mM citrate [18]. They suggested that citrate may inactivate
metalloenzymes in the venom gland by chelating essential metal cofactors. Both phosphodiesterase
and 5′-nucleotidase are Mg2+-dependent enzymes. It appears that citrate chelates Ca2+ more effectively
than Mg2+, a possibility also implied by Maguire and Cowan [19], who note that a 10× excess of EGTA
over Ca2+ in a given system would also chelate 20% of the Mg2+. Nonetheless, citrate does chelate
Mg2+ effectively, and many bacterial citrate transporters preferentially transport its Mg2+ salt [20].
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Figure 3. Structures of citric acid, cis-aconitic acid, and itaconic acid. cis-Aconitate is an intermediate
between itaconic acid a citric acid, in the citric acid cycle. It seems probable that itaconic acid
and cis-aconiti acid exist to suppo t citric acid pr duc ion i the venom glands. These tri arboxylic
acids chelate divalent cations to inactivate phospholipases, metalloproteases, nucleases, and other
metalloenzymes in the veno glan ; however, upon injection into prey tissues, these components are
immediately activated.
Odell et al. [21] reported citrate concentrations ranging from 42 to 154 mM (3.6–12.9%) in various
elapid, viperine, and crotaline venoms, including a value of 10.3% in Dendroaspis polylepis venom.
They also found that protease activity of Crotalus atrox venom against hide powder azure and azocasein
was inhibited 7.5%, and that of Bothrops picadoi venom was inhibited 78% with the addition of 18–27 mM
exogenous citrate. Thus, the citrate concentrations occurring in venoms should be more than ample
to inactivate metalloenzymes, especially considering that venom serine proteases, which do not
require metal cofactors, would not have been affected by this tr atment. Whil citrate ser es primarily
to protect the venom gland fr m metalloenzymes, giv n its high concentration in various venoms
documented in the foregoing studies and in the present one, it is likely that citrate also functions in
envenomation as an anticoagulant, by scavenging Ca2+ required by coagulation factors [22,23] and for
platelet aggregation [24,25].
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Figure 4. Organic acid abundances in sna s span nearly 8 orders of magnitude, based on
combined positive and negative i tensities, after subtraction of the blanks. The vast majority
are unq ably a cidental venom constituents, probably resulting from cellular degradation.
However, compounds with peak intensities above E 6, are probably sufficiently concentrated to make
substantive contributions to venom pharmacology. Baseline (noise) has been subtracted from all ion
intensities. Taxonomic names: Bmu, Bungarus multicinctus; Dp, Dendroaspis polylepis; Msp, Micrurus
spixii; Ms1–3, Micrurus surinamensis, 3 individuals; Nk, Naja kaouthia; Oh, Ophiophagus hannah;
Cc, Cerastes cerastes; Ds, Daboia siamensis; Apl, Agkistrodon piscivorus leucostoma; Bmo, Bothrops moojeni;
Cdt, Crotalus durissus terrificus; Cvv, Crotalus viridis viridis; Oo, Ovophis okinavensis; Pe, Protobothrops
elegans; Pf, Protobothrops flavoviridis.
2.2.2. Itaconic and cis-Aconitic Acids
Itaconic acid was also quite abundant in most venoms, reaching its highest concentrations in
viperine a d crotaline venoms (Figures 3 and 4, Supple entary Table S1). Like citric acid, for which
it serves as a precu sor via cis-aconitate, itaconic acid is also an excellent chelator of alkali and
alkaline earth metals, with iv lent cations being bound more strongly th n monovalent cations.
Using a methylene succinic linker, itaconic acid has been used with a polymeric matrix to make
chromatographic columns capable of resolving even very similar ion pairs, such as Ca2+ with Sr2+
or Mn2+ [26]. The literature has nothing to say about the metal chelation capacity of cis-aconitate,
but it is probably similar to that of citric acid. Venom itaconate levels are only slightly more highly
correlated with citrate levels (r2 = 0.9965) than with cis-aconitate (r2 = 0.9706). cis-Aconitate is also
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highly correlated with citrate (r2 = 0.9663). The high titers of venom citrate suggest that in venom gland
cells, C5-branched dibasic acid and citric acid pathways are being used in unusual ways. Itaconic
acid is converted to cis-aconitate by aconitate decarboxylase (EC 4.1.1.6). Normally, in the citric acid
cycle, aconitate hydratase (EC 4.2.1.3) catalyzes both the conversion of citrate to cis-aconitate and
cis-aconitate to isocitrate. It is not clear how the backward reaction could be promoted and the forward
reaction inhibited. However, the mass spectrometer cannot distinguish between citrate and isocitrate,
so perhaps much of the citrate is actually isocitrate. From the snake’s standpoint, this probably makes
no functional difference, as long as the subsequent step in the citric acid cycle, the conversion of
isocitrate to oxalosuccinate by isocitrate dehydrogenase (EC 1.1.1.42), is blocked.
2.3. Other Carboxylic Acids
In all, 37 organic acids were identified in the venoms we surveyed. Many more are undoubtedly
present, although probably at levels irrelevant to envenomation. Various fatty acids feature prominently
among these. However, other organic acids may serve toxic functions in the prey, rather than protective
or housekeeping functions in the venom gland. Nearly six decades ago, Curtis and Watkins [27]
demonstrated that various carboxylic acids and their α-decarboxylation products have opposing
actions on spinal neurons (Table 1), with the former being excitatory and the latter being inhibitory.
Table 1. Excitatory amino acids and their inhibitory α-decarboxylated derivatives, as determined on
rat spinal neurons [27]. Relative potency of the metabolite in question is indicated by the number of +
or − symbols. Most importantly, Curtis and Watkins [27] reported that when the α-carboxyl group
of the excitatory acidic amino acids is removed (lacking), the pharmacological action was completely
reversed, not merely diminished or abolished. Several of each were identified in venoms in this study.
Taurine, an aminosulfonic acid, is one of the most abundant amino acids in animal cells, and is a
significant constituent of all venoms investigated herein, particularly that of Bungarus multicinctus. See
Figure 13.
Acidic Amino Acid Excitation α-Decarboxylation Product Inhibition
Aspartic Acid + + + β-Alanine − − −
Glutamic Acid + + + GABA − − −
Cysteic Acid + + + Taurine − − −
β-Hydroxyglutamic Acid + + γ-Amino-β-hydroxy-n-butyric Acid − −
N-Methylaspartic Acid + + N-Methyl-β-Alanine − −
Aminomalonic Acid + Glycine − −
α-Aminoadipic Acid + δ-Aminoadipic Acid − −
α-Aminopimelic Acid + ε-Aminocaproic Acid −
N,N-Dimethylaspartic Acid + N,N-Dimethyl-β-Alanine 0
N-Methylglutamic Acid 0 N-Methyl-γ-Amino-n-butyric Acid 0
2.3.1. 4-Guanidinobutyric Acid
Three reactions are required to convert L-arginine to 4-guanidinobutyric acid (4GBA), also known
as 4-guanidinobutanoic acid (Supplementary Table S1, ID 6) and γ-guanidinobutyric acid (Figure 5);
thus, the latter is only two enzymatic reactions removed from 5-guanidino-2-oxopentanoic acid
(5G2OA). Overall, this was the second most abundant organic acid (Figures 4 and 5). Compounds
with imidazole or guanidinium groups inhibit the vasodilatory actions of KATP channel openers [28],
but since a hypertensive function would make little sense in envenomation by most snakes, like 5G2OA,
the pharmacological function of 4GBA is probably its capacity to induce seizures. Hiramatsu [29] and
Tachikawa and Hosoya [30] reported that accumulation of guanidino compounds in the brain may
induce epileptic discharges and convulsions. Jinnai et al. [31] found that cisternal injection of rabbits
with 5 mg/kg of 4GBA caused both tonic and clonic seizures, although intravenous injection of 5 or
25 mg/kg of 4GBA did not. The epileptogenicity of guanidino compounds apparently stems from their
inhibition of the inhibitory actions of GABAA and, possibly also, glycine receptors [32,33]. The failure
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of the nonbenzodiazepine anxiolytic drug, CGS 9896, to reverse the antagonism of GABA activity by
guanidino compounds, indicated that they act at a site distinct from the GABA binding site.Toxins 2018, 10, x FOR PEER REVIEW  9 of 51 
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Figure 5. The guanidino group of L-arginine is utilized in the production of nitric oxide (NO).
However, L-arginine can also be oxidized to 2-oxoarginine (2OA), a potent convulsant that exerts
its effects by blocking chloride channels of GABAA and glycine receptors. With two additional
enzymatic reactions, 2OA can be converted to γ-guanidinobutyric acid, which is also a convulsant.
Some guanidin compounds also reduce blood pressure and suppress “fight or flight” esponses in
rats nd aggr ssive behavior in cats. All of these ph rmacological effects are consistent with snake
envenomation strategi s [4].
Why do snakes employ both 5G2OA a 4 ? De Deyn et al. [34] found that inhibitory effects
of guanidine and methylguanidine on GABA were additive, and it is possible that 5G2OA and 4GBA
also act synergistically, likely by stimulating distinct sites on the GABAR (i.e., on the Cl− channel and
on an allosteric site), or on different subclasses of GABARs [33,35,36]. Both pharmacological activities
are capable of inducing epileptic seizures by reducing GABAergic inhibition in the central nervous
system [37–39].
The superior cervical ganglion is a part of the autonomic nervous system and is specifically
respon ible for “fight-or-flight” r ponses. Antagonism of GABAergic n urotransmission in the
posterior hypothal mus elicit escape locomotor behavior in rats [40], whereas stimulation of
GABAergic signaling suppresses s ch behavior, which would be to the advantage of the snake.
Kása et al. [41] and Wolff et al. [42] found that GABAergic axons are distributed unevenly within
the superior cervical ganglion. GABAergic innervation of the soma and the stem dendrites of a
subpopulation of principal ganglion cells was especially significant, suggesting that GABAergic
innervation is critical to the function of this ganglion. Two enzymes involved in GABA metabolism,
glutamate decarboxylase and GABA-transaminase, have also been localized in neurons of sympathetic
ganglia [43,44]. Galva et al. [45] reported that in the rat isolated superior cervical ganglion,
in 4-aminopyridine solution (200–300 µM), 100 µM G BA, evoked “b rsts” of spikes and EPSPs,
in addition to euronal depolarization.
Relative to envenomation, the importance of 4GBA’s action in the superior cervical ganglion may
pertain to its agonism of GABA receptors. 4GBA depolarized rat superior cervical ganglia in the same
manner as GABA, but with only about 1% the potency thereof [46]. Siegel and Schubert [47] reported
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that a GABAergic pathway from medial to lateral hypothalamus suppresses aggressive behavior in
cats. Nonetheless, it is unclear whether the quantities of 4GBA detected here would be sufficient to
affect the superior cervical ganglia, even if it does act as suggested.
Takahashi et al. [48] reported that iv injections of GABA in anesthetized rabbits produced
hypotension and bradycardia. Similar results were obtained with GABA injections into
dogs, cats, and rats [49–51]. Serafin et al. [52] found that 2-guanidino-benzimidazole and
2-guanidino-5-aminobenzimidazole dihydrochloride had hypotensive activity, comparable to that
of aminophylline. Thomas et al. [53] reported that two guanidino compounds, L-homoarginine and
L-amino-tau-guanidino butyric acid, behave like L-arginine in reversing the vasoconstrictor effect of
L-NMMA, in a stereospecific and concentration-dependent manner. However, L-amino guanidino
propionic acid and guanidine were ineffective. Thus, as guanidino compounds, both 5G2OA and
4GBA may be hypotensive, which would be consistent with snake envenomation strategies [4].
4GBA may also have antimicrobial actions in the venom gland, given that 4GBA and other
guanidino acids are effective at suppressing bacillus and coccus infections [54]. However, such action
would likely be secondary to a role in envenomation.
2.3.2. 5-Guanidino-2-oxopentanoic Acid
5-Guanidino-2-oxopentanoic acid (5G2OA), also known as 2-oxoarginine, is the first metabolite of
arginine catabolism (Figure 5). 5G2OA was the third most abundant organic acid among the venoms
we surveyed, based upon their maximal concentrations (Supplementary Table S1, ID 22). 5G2OA
levels are increased in patients with argininemia, a deficiency of the enzyme arginase (EC 3.5.3.1).
Among arginine metabolites, 5G2OA has been especially implicated in the central nervous system
damage that occurs in that disease [55]. De Deyn et al. [35,36] first suggested that the convulsant effects
of 5G2OA in rabbits might be due to a blockade of chloride channels associated with GABA and glycine
receptors, thus inhibiting responses to these inhibitory neurotransmitters. Later, GABAA receptors
were specifically implicated [33] in its convulsant effects.
2.3.3. Imidazole-4-acetic Acid
Imidazole-4-acetic acid (I4AA) (Figure 6) is the fifth most abundant carboxylic acid occurring in
the venoms we tested. Found in the brains of mammals, it is a naturally occurring histidine metabolite
that is structurally similar to GABA [56–61]. Numerous studies have reported I4AA pharmacology
that is consonant with snake envenomation. When applied iontophoretically to cat cortical neurons
stimulated with glutamate, I4AA inhibited neuronal firing in a manner similar to GABA [62], but with
a slower onset [63]. Roberts and Simonsen [64] found that I4AA had sedative and analgesic effects
when injected ip (4 µg/g) into mice. A subsequent study from the same group reported that mice
injected with increasing doses from 1 to 3 µmol/g displayed hyperactivity, ataxia, catalepsy and,
finally, complete loss of a righting reflex [65]. Similar results were obtained in rats. Tunnicliff et al. [66]
discovered that I4AA injected ip into mice at 3 µmol/g caused body temperature to decrease steadily
over a 2 h time course. Sooriyamoorthy et al. [67] found that I4AA (500 mg/kg) in conscious rats
decreased cerebral blood flow by 42%.
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Figure 6. Imidazole-4-acetic acid, (left) an ago i alian GAB A receptors. The natural
agonist, γ-amino butyric acid, or GABA, is sho o t e right.
Roberts [68] reported that I4AA displaces 3H-GABA from receptor-related membrane sites with
an IC50 of 1.3 µM (Figure 6). I4AA acts as an agonist at GABAA receptors [59,69,70], and has been
reported as everything from a partial agonist to a strong antagonist at GABAC receptors [56,61,70–75].
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Binding of the ligand, GABA, to GABAA or GABAC receptors, opens a chloride channel [76].
Whereas GABAA receptors produce rapid, transient responses, GABAC receptors promote rapid,
prolonged responses [77]. While GABAC receptors are widely distributed, they are much less abundant
than GABAA and GABAB receptors [78], and their pharmacology and response speed do not seem
particularly pertinent to envenomation.
On the other hand, GABAA receptors are ionotropic, and occur as heteropentamers [79].
GABAA agonists reduce neuronal excitability and exhibit sedative effects [80]. For instance, the partial
GABAA agonist, MRK-409, induces sedation in humans at only ~10% receptor occupancy. I4AA inhibits
the firing of CNS neurons [62]. It readily crosses the blood–brain barrier when administered
systemically, whereupon it decreases blood pressure and heart rate by agonizing GABAA receptors in
the CNS [81]. Both effects accord perfectly with the envenomation strategies identified by Aird [4].
Roberts and Simonsen [82] discovered that I4AA activates 3′,5′-nucleotide phosphodiesterase by
binding to an allosteric site. Since this enzyme degrades cAMP to AMP, the latter, which is somewhat
hypotensive, can be dephosphorylated to release adenosine, which is strongly so. Thinking that a
decrease in cAMP might reduce blood pressure, Walland [83] injected I4AA into the lateral ventricle of
the brain in cats, and found that it elicited dose-dependent hypotension.
In vertebrate retina, the taurine transporter (TAUT) is largely responsible for retinal transport
of GABA, in contrast to the brain, where the GABA transporter has a larger functional role [84].
Retinal taurine influx is significantly inhibited in a concentration-dependent manner by both GABA
and by I4AA [85]. GABA transporter 2 (GAT-2, also known as BGT-1) is also a taurine transporter [86],
although its affinity for GABA is ~30× higher than its affinity for taurine [87,88]. It is unclear whether
I4AA also inhibits GAT2, although this would not be surprising.
2.3.4. 4-Hydroxyphenylacetic and 4-Hydroxyphenylpyruvic Acids
4-Hydroxyphenylpyruvic acid (4HPPA) (Figure 7), like 4-hydroxyphenylacetic acid (4HPAA), occurs
at moderate levels in all crotaline venoms (Figure 4). It is essentially absent from Dendroaspis polylepis
venom, and is minimal in most other elapid venoms. Very little is known about this compound.
The biomedical literature is likewise all but silent on it. However, tyrosine can be catabolized by
tyrosine aminotransferase (EC 2.6.1.5) to form 4HPPA and glutamate [89]. 4HPPA, in turn, can be
converted to homogentisic acid by the action of 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27).
Szwajgier [90] reported that of nine phenolic acids tested, homogentisic acid and 4HPPA were the most
effective acetylcholinesterase inhibitors, using the spectrophotometric method of Ellman et al. [91];
however, many phenolic acids are inhibitors of both acetylcholinesterase and butylcholinesterase [92].
This inhibitory activity would be consistent with the mamba envenomation strategy, thus, its complete
absence from D. polylepis venom is unexpected (Figure 4), raising the question of whether this really is
its primary function.
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Figure 7. Structure of 4-hydroxyphenylpyruvic acid, an inhibitor of acetylcholinesterase produced by
the action of venom L-amino acid oxidase on tyrosine [93].
Nucaro et al. [93] reported that in vitro, Taiwan cobra (Naja atra) venom is able to convert tyrosine
into phenolic oxidation products via 4-hydroxyphenylpyruvate (Figure 7). They found that tyrosine
was released from neuropeptides by oligopeptidases in the venom. Nucaro et al. [93] determined
that venom L-amino acid oxidase (LAO) initially releases the keto form of 4-hydroxyphenylpyruvic
acid and hydrogen peroxide using tyrosine as a substrate. They asserted that, thereafter, a venom
tautomerase effects a partial conversion of the keto form of 4HPPA into an enol. The latter is
oxidized to 4-hydroxybenzaldehyde and 4-hydroxyphenol, while the keto form is oxidized to
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4-hydroxyphenylacetic acid by H2O2 co-released from tyrosine by LAO. Utilizing both of these
oxidation routes, Naja atra venom generates still other phenolics [93]. Whether the venom titers of these
compounds are sufficient to influence prey envenomation is debatable. Nonetheless, it seems likely
that quantities of 4HPPA and 4HPAA released in the prey by venom enzymes may well be significant.
2.3.5. Indole-3-acrylic Acid
Xanthine oxidase oxidizes hypoxanthine to xanthine for subsequent conversion to uric acid,
but degradation of hypoxanthine is blocked by indole-3-acrylic acid (I3AA), which inhibits xanthine
oxidase with an IC50 of 136 µM [94]. Therefore, indole-3-acrylic acid could potentially contribute to
inosine accumulation in the venom gland, or it may block degradation of hypoxanthine to xanthine by
prey xanthine oxidase, driving conversion of hypoxanthine to inosine by prey enzymes.
Kynurenine aminotransferase (KAT1) converts kynurenine into kynurenic acid, an inhibitor of
NMDA glutamate receptors [95–98] and α7-nicotinic (neuronal) acetylcholine receptors [96,97,99].
I3AA inhibits human KAT1, thereby blocking formation of kynurenic acid [100]. As a result,
the net effect of I3AA on NMDA iGluRs and α7 nAChRs would depend upon the balance between
exogenous and endogenous agonists and antagonists, a balance that could differ depending upon the
snake involved. Interestingly, mamba (Dendroaspis) venoms, arguably the most excitatory snake
venoms known, do not contain I3AA. However, this is probably because they already contain
dendrotoxins [101,102], fasciculins [103–105], and acetylcholine [106]. This combination presumably
floods nicotinic synapses with neurotransmitter, causing fasciculations and, also, promotes hypotension
via vascular M3 muscarinic AChRs [107–110]. For a review of muscarinic receptors in snake
envenomation, see Aird et al. [16].
I3AA (Figure 8) is also a potent inhibitor of mammalian tryptophan 2,3-dioxygenase, although it
does not inhibit indoleamine 2,3-dioxygenase, an enzyme that degrades 5-hydroxytryptamine and
serotonin [111]. Tryptophan 2,3-dioxygenase deficiency results in neuroprotection because it degrades
tryptophan to kynurenine, a precursor to kynurenic acid (Figure 9). Interestingly, the two related
compounds have opposing pharmacologies [112]. Kynurenines, such as quinolinic acid are excitatory,
while kynurenic acid is inhibitory.
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Figure 9. Structu es of L-kynurenine (left) and ky urenic acid (right). L-kynurenines such as quinolinic
acid are excitatory, but kynurenic acid, produced from L-kynurenine by the action of ky urenine
aminotransferase (KCAT1), is an inhibitor of NMDA iGluRs and α7 nAChRs. I3AA inhibits KCAT1,
blocking production of both molecules by this pathway.
Lastly, I3AA also potently inhibits D-dopachrome tautomerase, an isomer of macrophage
migration inhibitory factor (MIF) [113]. Despite its discovery decades ago, the natural substrate
of MIF remains unidentified [114]; hence, it is impossible to say exactly what effects its blockade by
I3AA might have.
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2.3.6. 5-Aminolevulinic Acid
Hermes-Lima [115] reported that 5-aminolevulinic acid (Figure 10) generates oxygen radicals
in vitro and, possibly, in vivo during pathologic situations in which its concentration is elevated.
The damage is ascribed primarily to –OH radicals. Bechara [116] found that 5-aminolevulinic acid
undergoes transition metal-catalyzed oxidation to yield O−2, H2O2, and HO−. 5-Aminolevulinic acid
was present in all venoms at low to very low concentrations (Figure 4). Oddly, it was most abundant
in venoms of B. multicinctus and D. siamensis.
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Figure 10. Struct f -a inolevulinic acid.
2.4. Purine Nucleosides
2.4.1. Adenosi e
Adenosi e contributes t prey immobil zation by activation of n uro al adenosine A1
receptors [117–124], suppressing acetylcholine release from motor neurons [125–130] and excitatory
neurotransmitters from central sites [131–133]. It also exacerbates venom-induced hypotension
by activating A2 receptors in the vasculature, and by depressing cardiac output and causing
atrioventricular block [134–141]. Inosine potentiates the coronary vasodilatory effects of
adenosine [142,143]. Aird [144] also reviewed numerous secondary effects of adenosine that are
germane to snake envenomation.
The most abundant small organic compounds overall were adenosine and adenine, owing principally
to their extremely h gh conc ntrations in Dendroa pis polylepis venom, which exce ded the levels found in the
remaining 16 venoms by 1–4 orders of magnitu (Figures 2 and 11, Supplementary Table S1). High levels of
adenosine have previously been reported for Dendroaspis angusticeps venom [12,145]. Aird [4,144] proposed
that purine nucleosides (adenosine, inosine, and guanosine) are central to the envenomation strategies
of nearly all venomous snakes, either as exogenous components co-injected with proteinaceous toxins,
or as endogenous secondary messengers released from prey tissues by the action of enzymatic venom
constituents. The first part of that hypothesis has been amply documented [12,145–149], and several recent
studies have also provided strong support for the second part.
Cintra-Francischinelli et al. [150] reported that Bothrops asper myotoxins release large quantities
of ATP and K+. Building upon that earlier work, Caccin et al. [151] provi ed elegant proof that the
purified catalytic (Asp49) and non-catalytic (Lys49) phospholipase myotoxins from Bothrops asper
venom induce rapid release of ATP from mouse skeletal muscle, as predicted. Contrary to their
expectations that crude ve om would release even more, it did not seem to do so. This apparent
contradiction was explained by the fact that the crude venom contains both phosphodiesterase and
5′-nucleotidase, which rapidly degrade ATP to adenosine. They concluded that high concentrations of
adenosine are released by the combined myotoxic and enzymatic activities of the venom and that the
adenosine contributes to prey immobilization.
Likewise, Tonello et al. [152] found that even at sublytic doses, Mt-II, the non-catalytic myotoxin
from Bothrops asper venom, duced a dose-dependent release of ATP from mouse macrophages,
triggering Ca2+ release from intracellular stores that resulted in cell death in less than 1 h. The cell
death process appears to involve binding of Mt-II to PX1, 2, or 3 receptors, as well as to PY12 and
PY13 receptors, which results in further ATP release [152]. However, the ini ial releas of ATP may be
involved in a positive feedback loop that facilitates the second release.
In addition to adenosine, other purines, adenine, inosine, hypoxanthine, guanosine, guanine,
xanthine, a d xanthosine, are als present, with all but xanthine and anthosine ranking among
the top 43 metaboli es. While the purine bases, adenine, hypoxanthine, and gu ni e, may have
Toxins 2018, 10, 392 13 of 49
pharmacological actions that are consonant with ophidian envenomation strategies, we propose that
they exist in venoms primarily as substrates for conversion to their corresponding nucleosides by
purine-nucleoside phosphorylase (EC 2.4.2.1) (Figure 12). In possible support of this contention,
regression analysis showed that concentrations of all three bases are highly correlated with
concentrations of their nucleosides for the 17 species examined here (adenine–adenosine, r2 = 0.444
(p = 0.0035); hypoxanthine–inosine, r2 = 0.8174 (p < 0.0001), guanine–guanosine, r2 = 0.9522,
(p < 0.0001)) (Figure 13a–c).
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Figure 11. Purine nucleosides and t ir ba es are s g ificant constituents of elapid, viperine,
and crotaline venoms. Elapid and viperine venoms contain greater quantities of them than
crotaline venoms. The purine strategy of D. polylepis is particularly noteworthy. Taxonomic
names: Bmu, Bungarus multicinctus; Dp, Dendroaspis polylepis; MSP, Micrurus spixii; Ms1–3, Micrurus
surinamensis, 3 individuals; Nk, Naja kaouthia; Oh, Ophiophagus hannah; Cc, Cerastes cerastes; Ds, Daboia
siamensis; Apl, Agkistrodon piscivorus leucostoma; Bmo, Bothrops moojeni; Cdt, Crotalus durissus terrificus;
Cvv, Crotalus viridis viridis; Oo, Ovophis okinavensis; Pe, Protobothrops elegans; Pf, Protobothrops flavoviridis.
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Figure 12. Elapid and viperine venoms contain i levels of purine nucleosid s, whil crotaline
venoms tend to have trace quantities [4,12]. However, crotaline v noms accomplis t s e objective
by releasing purines from prey tissues. Venom purines isolated during this study are indicated by
red dots. Interestingly, blockade of xanthine oxidase by venom indole-3-acrylic acid might drive
hypoxanthine toward inosine or adenine in the venom gland; however, it is most abundant in crotaline
venoms (Figure 11), which hav very low pur ne titers. Therefore, this function seems unlikely.
Perhaps it serves a similar function in prey tissues. Venoms also contain much lower levels still of
N6-methyladenine, an inhibitor of both adenine and guanine deaminases; however, this compound is
most abundant in mamba venom, which employs a purinergic envenomation strategy. Thus, it may
support adenosine synthesis in some fashion, perhaps by blocking the backward conversion of adenine
to hypoxanthine.
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nucleosides, the roles in envenomation of which ave been well c aracterized. Ovophis okinavensis
was excluded from plot 13a bec no adenine was detected in that venom. Elapids, red;
viperines, green; and crotalines, blue. Taxonomic abbreviations: Apl, Agkistrod n pisciv rus leucostoma;
Bmo, Bothrops oojeni; Bmu, Bungarus multicinctus; c, Cerastes cerastes; Cdt, Crotalus durissus terrificus;
Cvv, Crotalus viridis viridis; Ds, Daboia siamensis; Dp, Dendroaspis polylepis; Mss, Micrurus spixii spixii;
Ms1–3, Micrurus surinamensis 1–3; Nk, Naja kaouthia; Oh, Ophiophagus hannah; Oo, Ovophis okinavensis;
Pe, Protobothrops elegans; Pf, Protobothrops flavoviridis.
2.4.2. Inosine
Inosine potentiates the coronary vasodilatory effects of adenosine [142,143]. Like adenosine,
inosine activates mast cell A3 receptors, liberating vasoactive substances and increasing vascular
permeability [153–156]. Fuentes et al. [157] reported that like adenosine, inosine inhibited platelet
aggregation and ATP release stimulated by ADP and collagen. Both nucleosides significantly prevented
thrombus formation in vivo, apparently acting at platelet adenosine A2A receptors. Other reports also
suggest that inosine is capable of acting as an A2A receptor agonist [158,159]. Since the half-life of
inosine (15 h) in vivo is much longer than that of adenosine (10 s), inosine provides a way of extending
the pharmacological action of adenosine at A2A receptors [160]. Inosine has been identified as an
endogenous ligand of the benzodiazepine binding site of GABAA receptors [161], suggesting that it
may contribute to sedation and ataxia [162] caused by adenosine [163].
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2.4.3. Guanosine
Aird [12] noted that guanosine tends to be more abundant in venoms of snakes that prey
upon reptiles, amphibians, or fish. That pattern holds for this dataset as well. Micrurus spixii
presented the highest levels of both guanosine and guanine, followed by B. multicinctus and O. hannah,
Daboia siamensis actually had slightly more elevated levels than O. hannah, but nothing is known
about the prey preferences of this taxon. Interestingly, venom of P. elegans, a small habu from the
Sakishima Islands in western Okinawa Prefecture that feeds largely on lizards, has much higher levels
of guanosine and guanine than the closely related P. flavoviridis, from Okinawa Island, which attains
lengths of 2.5 m, and which feeds almost entirely on small mammals upon reaching adulthood.
Upon intradermal injection in humans, xanthosine causes pain, but unlike inosine and guanosine,
it does not liberate histamine [164]. Hayashi et al. [165] reported that inhibition of neurotransmitter
release from guinea pig ileal strips was shifted to the right by xanthine derivatives; thus, xanthosine
acts as an adenosine inhibitor, and its known pharmacological activities run contrary to snake
envenomation strategies [4]. Xanthosine shows a definite phylogenetic distribution in venoms.
While crotaline venoms are essentially devoid of it, xanthosine is variably present in elapid and
viperine venoms, but at very low levels. In fact, in our second analysis, xanthosine was not detected,
owing to a loss of sensitivity. Given its pharmacology, why would it be present in any snake venoms?
The answer appears to be that xanthosine concentration correlates well with guanosine concentration
(Figure 13c), suggesting that it exists in venom primarily for conversion to guanosine by guanosine
aminohydrolase (E.C. 3.5.4.15) (Figure 12).
2.4.4. Ethyl Adenosine Carboxylate (EAC)
A form of ethyl adenosine carboxylate (EAC) is present in D. polylepis venom at very high
concentrations (Figure 11). It appears in trace quantities in all other venoms, except that of
B. multicinctus, which is entirely negative. Fragmentation was inadequate to identify to isomer that
occurs in D. polylepis venom, and attempts to fragment it further upon re-isolation were not successful.
Only one isomer, ethyl adenosine-5′-carboxylate, appears in the biomedical literature.
Imai et al. [166] reported that, in doses >30 µg, EAC produced a pronounced, transient increase
in coronary blood flow in dogs, accompanied by slight bradycardia. Adenosine, in doses >1 mg,
produced similar effects to those of EAC, except that the bradycardia was more pronounced and
of briefer duration. The authors concluded that EAC exerted a direct vasodilatory effect on the
coronary vasculature. EAC’s effects were antagonized by aminophylline in the same fashion as those
of adenosine [166]. Moreover, those effects were not potentiated by dipyridamole, an adenosine
potentiator. EAC’s pharmacology would be entirely consistent with the Dendroaspis purine-based,
hypotensive, envenomation strategy [4].
2.4.5. Minor Purines
After guanine, the next most abundant purine was an unidentified compound that is most
likely a non-standard purine base derivative, devoid of sugar (Figure 11). It is quite abundant in
D. polylepis venom, suggesting that it is no artefact. Unfortunately, this compound underwent very
little fragmentation, thwarting attempts to identify it.
1-Methylguanine, 7-methylguanosine, and N6-methyladenine were also found in various venoms,
but at concentrations 2–5 orders of magnitude lower than the concentrations of EAC found in
D. polylepis venom (Figure 11, Supplementary Table S1). 1-Methylguanine and 7-methylguanine,
metabolic products of tRNA degradation, induced a 50% increase of Con A-mediated hemadsorption
within 20 h of exposure of the cells to the agent at a concentration of 10−5 M [167,168]. It may be that
these compounds promote platelet aggregation, or stimulate mast cells, since they affect membrane
characteristic of blood cells. However, they are present in very small quantities, and may not have
a significant effect on any physiological parameter in the prey; however, titers are higher in elapid
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and viperine venoms than in crotaline venoms. The 1- and 7-methyl isomers cannot be distinguished
readily by mass spectrometry.
N6-Methyladenine is present in most, if not all, invertebrates and vertebrates at very low levels.
Evolutionarily, it is a highly conserved epigenetic marker that governs gene expression [169]. It is
present in snake venoms (Figure 11) at levels that may approach housekeeping levels; nonetheless, it is
most abundant in D. polylepis and C. cerastes venoms (Figure 11). N6-Methyladenine has been reported
to depress cholinergic neurotransmission [170].
2′-Deoxyadenosine was the least abundant purine that we identified; however, its highest
concentrations were found in D. polylepis and C. cerastes venoms (Figure 11). 2′-Deoxyadenosine
was found to stimulate neurotransmitter release at cholinergic sites [170].
2.5. Neurotransmitters
2.5.1. Acetylcholine
The fifth most abundant organic metabolite in these venoms was acetylcholine, again, owing
to its high concentration in Dendroaspis polylepis venom [106,171]; however, it was present in
all others, albeit at 4–5 orders of magnitude lower abundance than in black mamba venom
(Figure 2). Mamba venom acetylcholine targets principally vascular muscarinic receptors promoting
vasodilation, the nicotinic neuromuscular junction and, probably secondarily, central nicotinic
receptors [4]. Mamba venoms employ an excitatory strategy. In addition to containing
acetylcholine, they also possess dendrotoxins, which promote acetylcholine release from nicotinic
endplates [101,172], and fasciculins, which function as acetylcholinesterase inhibitors [103–105].
Cobras (Naja, Ophiophagus, Hemachatus) adopt a paralytic strategy involving postsynaptic nicotinic
receptor antagonists and acetylcholinesterase, so acetylcholine would make no sense as a toxin in
these venoms.
2.5.2. γ-Aminobutyric Acid
Bothrops moojeni venom contained potentially significant concentrations of γ-aminobutyric acid
(GABA), an important inhibitory neurotransmitter (Supplementary Table S1). Titers in all other venoms
were 1–3 orders of magnitude lower. As noted in the section on 4GBA, the superior cervical ganglion
is a part of the autonomic nervous system and is specifically responsible for “fight-or-flight” responses.
Binding of GABA to its receptors on the superior cervical ganglion suppresses escape locomotor
behavior in rats [40], which would be advantageous to the snake. Whether the concentrations of GABA
in B. moojeni venom are sufficient to suppress escape in rodent prey, or ground doves, on which this
snake also feeds, is an open question.
2.6. Amines and Alkaloids
The venoms examined here contained a variety of amines, many of which are tertiary
or quaternary amines (Figure 14). Polyamines, which are among the most significant amines
pharmacologically and, perhaps, in terms of abundance as well, were not detected in this study
because detection with LC-MS requires derivatization [173]. Derivatization could not be used here as it
would have hopelessly complicated identification of other compounds. However, N-acetyl-putrescine
occurs naturally in venoms, and was detected in potentially significant quantities in the venoms of
D. polylepis, D. siamensis, and C. d. terrificus. As a group, amines are interesting because while some of
them occur in more or less all venoms examined, several of the most abundant show greatly elevated
concentrations specifically in one to several venoms (Figure 14). The most important classes of amines
in snake venoms are derivatives of creatine/creatinine, carnitine, and choline.
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Figure 14. Various amines and cholines (quaternary amines) were identified in the 17 snake venoms.
Most were present at low levels, suggesting that functional roles in envenomation are improbable.
Others showed modest to high concentrations in specific taxa, but were essentially absent in
others. Examples of this pattern include acetyl-L-carnitine, proprionyl-L-carnitine, triethylenediamine,
histamine, and 5-aminopentanamide. Taxonomic names: Bmu, Bungarus multicinctus; Dp, Dendroaspis
polylepis; Msp, Micrurus spixii; Ms1–3, Micrurus surinamensis, 3 individuals; Nk, Naja kaouthia;
Oh, Ophiophagus hannah; Cc, Cerastes cerastes; Ds, Daboia siamensis; Apl, Agkistrodon piscivorus leucostoma;
Bmo, Bothrops moojeni; Cdt, Crotalus durissus terrificus; Cvv, Crotalus viridis viridis; Oo, Ovophis okinavensis;
Pe, Protobothrops elegans; Pf, Protobothrops flavoviridis.
2.6.1. Creatine and Creatinine
Creatine and analogs, such as cyclocreatine, have antitumor, antiviral, and antidiabetic effects,
and protect tissues from hypoxia, ischemia, neurodegeneration, or muscle damage [174], but these
effects are difficult to reconcile with functions essential to envenomation. Creatine has a central role
in ATP synthesis, where it acts as a phosphate group acceptor to form phosphocreatine. The latter,
in turn, acts as a donor of phosphate for conversion of ADP to ATP via the action of creatine kinase
(EC 2.7.3.2).
Creatinine reportedly has anticonvulsant activity in the CNS [175], but as with the physiological
functions of creatine, this appears to be inconsistent with the objectives of snake envenomation.
Creatinine is a catabolite of creatine in the arginine metabolic pathway. In the absence of any obvious
pharmacology consistent with prey debilitation, we suggest that, like the carnitines, the primary
role of creatine is probably to support venom protein synthesis via ATP production, and that the
concomitantly high levels of creatinine probably reflect creatine metabolism. While creatinine levels
are indeed correlated with creatine levels (r2 = 0.568, p = 0.0005), the two compounds show no apparent
relationship with either phylogeny or biology (Figure 15), supporting the hypothesis of a metabolic role,
rather than a strategic function. If this hypothesis is correct, the apparent ubiquity of this metabolite
(Figure 14) could be taken as support for a non-strategic function.
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2.6.2. Carnitines
Like choline, L-carnitine and its derivatives, acetyl-L-carnitine, and propionylcarnitine, all of which
are found in some venoms, are also quaternary ammoniu compounds. Acetyl-L-carnitine (ALC) is
derived from acetylati n of carniti e in mitochondria. I addition to transporting long-chain fatty
acids to mitochondria for β-oxidation, ALC provides acetyl groups f r acetylcholine sy thesis, xerts a
cholin rgic effect, a d can be incorpor ted into glutamate, glutamine, and GABA [176]. Mamba venoms
have high levels of both acetylcholine and ALC (Supplementary Table S1). In fact, the D. polylepis
ALC level exceeds that of most other venoms by 3–4 orders of magnitude, suggesting that its primary
function in venoms is as a precursor for acetylcholine. Secondarily, at supraphysiologic concentrations,
ALC is neuroprotective in animal models of cerebral ischemia [177–180]. Neuroprotection is
accomplished by suppression of neuronal activity, which would be consonant with snake envenomation
strategies [4].
Only the venom of D. polylepis showed a relatively high concentration of proprionyl-L-carnitine,
although it was al o present in the venoms of M. surinamen is, C. cerastes, A. p. leucos oma, and the
two Protobothrops sp cies (Figure 14). Proprionyl-L-carnitine acts irectly upon vascular e ithelium
to activate endothelial nitric oxide synthase, resulting in the production of nitric oxide, a potent
vasodilator [181]. It also counteracts the vasoconstrictor activity of endothelin [182].
2.6.3. Choli es
In addition to acetylcholine, mentioned above, venoms also contain choline itself, and choline
phosphate (Supplementary Table S1). Interestingly, choline is most abundant in venoms of
D. siamensis, B. multicinctus, and C. d. terrificus, rather than in D. polylepis, as might have been anticipated
due to its high acetylcholine content. Nor do choline levels mirror those of choline phosphate, which is
most abundant in A. p. leucostoma venom.
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2.6.4. Betaines
Glycine betaine, a trimethyl derivative of glycine, was the sixth most abundant amine in the
venoms we examined. Betaine’s role as a methyl donor is well known [183], as is its function
as an osmolyte [184,185]. A betaine-GABA transporter, BGT-1, was isolated from dog kidney by
Yamauchi et al. [186], and that same year, a highly similar GABA transporter was isolated from
mouse brain [187]. Schousboe et al. [188] concluded that BGT-1 receptors govern seizure susceptibility,
but what role they play is unclear. Borden and colleagues [189,190] found that BGT-1 is widely
distributed throughout the human brain and outside the central nervous system, but in the CNS its
distribution is largely astrocytic.
On the basis of plasma and urine concentrations, Lever et al. [191] concluded that glycine
betaine, but not proline betaine [192], is important in the biochemistry of humans and other mammals.
Snakes do not accumulate compounds in their venoms unless they contribute to prey immobilization
or serve a function in the venom gland. If so, then why do all snake venoms examined contain modest
to significant amounts of glycine betaine and roughly 12-fold lower levels of proline betaine?
Presently, four classes of GABA transporters have been identified: GAT-1, GAT-3, GAT-4,
and GAT-2, which is the same as BGT-1 [186]. BGT-1 also transports glycine betaine in addition
to GABA. Matskevitch et al. reported that oocytes expressing BGT-1 were equally depolarized by
1 mM glycine betaine or GABA [193]. Takanaga et al. [194] found that BGT-1 is expressed at the
blood–brain barrier (BBB) and participates in GABA transport across the BBB. They found that GABA
transport across the BBB was inhibited by 22% using 0.5 mM glycine betaine and Barakat et al. [195]
reported that ≥200 µM betaine is a competitive blocker of BGT-1 transporters.
When GABA transporters in neuronal and glial cells are inhibited with nipecotic acid, GABA
diffuses from the brain into the bloodstream in rats [196]. Efflux of GABA across the blood–brain
barrier may compensate for normal GABA reuptake by neuronal and glial cells [194].
It is possible that venom glycine betaine interferes in some way with prey GABA levels. Given
that venoms contain various small metabolites that function as GABA agonists and that are also
pro-convulsants (2-OA, 4GBA, I4AA), it is possible that betaine also acts as a pro-convulsant. On the
other hand, GABAA receptor agonists produce sedation at only 10% occupancy [80]. It may be that
inhibitory concentrations of glycine betaine block BGT-1, augmenting local concentrations of GABA,
thereby inducing sedation, hypotension, and bradycardia [81].
Proline betaine, also known as stachydrine, most likely has a different function. It has been
shown to improve endothelial cell viability and to inhibit cell senescence by modulating p16INK4A,
a tumor suppressor protein that transduces senescence signals to drive cells into senescence [197–199].
In hyperglycaemia, proline betaine counteracts the harmful effects of high blood glucose by
downregulating p16INK4A levels and by blocking inhibition of SIRT1. Mercken et al. [200] found that
SRT2104, a synthetic small molecule activator of SIRT1, extended both mean and maximal lifespan of
mice. It is impossible to draw any firm conclusions at this point but, hypothetically, given its beneficial
effects on endothelial cells and its apparent ubiquity in snake venoms (Figure 14), perhaps proline
betaine serves to extend the longevity of venom gland epithelial cells.
2.6.5. Taurine
Taurine is technically an amino sulfonic acid, since it lacks a carboxyl group. Nonetheless, it is
one of the most abundant amino acids in mammals [201]. It occurs in virtually all tissue types at
relatively high concentrations, and impacts a wide variety of biological processes, a number of which
are pertinent to envenomation.
Nearly six decades ago, Curtis and Watkins [27] and, later, Curtis et al. [62], reported that
iontophoretically applied taurine has a depressant effect on cortical neurons and spinal interneurons.
Pasantes-Morales et al. [202] found that, in chicken retina, application of taurine depressed the b-wave
of the electroretinogram, a finding confirmed by Bonaventure et al. [203] for intravitreal injections
of taurine. They reported that the depressant action of taurine, but not of GABA, was abolished by
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strychnine, an antagonist of glycine and acetylcholine receptors. Conversely, picrotoxin, an antagonist
of GABAC receptors, abolished the depressant action of GABA, but not taurine. These findings
were significant because Curtis et al. [204,205] had earlier shown that GABA-like amino acids act
presynaptically, and are antagonized by picrotoxin and bicuculline; whereas glycine-like amino acids
are blocked by strychnine and act postsynaptically. Bonaventure et al. concluded that both taurine and
GABA act as inhibitory neurotransmitters in the retina [203].
Okamoto et al. [206] showed that the hyperpolarizing action of taurine on Purkinje cell
dendrites in guinea pig cerebellar slices was selectively and competitively antagonized by 200 µM
TAG (6-aminomethyl-3-methyl-4H,1,2,4-benzothiadiazine-1,1-dioxide), an amino acid antagonist,
while actions of GABA, glycine and beta-alanine were scarcely affected. TAG reversed the
hyperpolarization induced by exogenously applied taurine at the same potential, and 200 µM
TAG completely and reversibly blocked the synaptic potential. Okamoto et al. [206] suggested
that taurine may be an inhibitory neurotransmitter in stellate neuronal synapses on Purkinje cell
dendrites. Lin et al. [207] subsequently proposed that taurine might be used by amacrine cells
as a neurotransmitter in rabbit retina. Kamisaki et al. [208] found that addition of 10 µM taurine
to the Ca2+-free medium perfusing rat cerebral cortical synaptosomes significantly reduced the
depolarization-evoked release of Glu, Asp, and GABA. The taurine-induced reduction in GABA
release was attenuated by phaclofen, a GABAB antagonist, but not by bicuculline, a GABAA antagonist.
However, these antagonists did not block the effects on Glu and Asp release. Taurine released by
neurons appears to suppress further transmitter release in much the same fashion as adenosine [4].
Lombardini [209] reported that taurine stimulates ATP-dependent calcium ion uptake and
inhibits protein phosphorylation; however, Foos and Wu [210] found that taurine strongly inhibits
45Ca2+ influx with no effect on efflux. Under prolonged L-glutamate stimulation, neurons release
significant (mM) amounts of taurine, which then acts extracellularly to reduce cytoplasmic Ca2+ levels
by acting upon both transmembrane ion transporters and intracellular storage pools. Specifically,
taurine prevents Na+/Ca2+ ATPase from operating in reverse mode under exocytotic conditions
(whereby the ATPase pumps Ca2+ in instead of out). In addition, taurine reduces the production of
IP3 in both control and glutamate-stimulated cells, which, in turn, blocks the release of Ca2+ from
intracellular stores [210]. Later, Wu et al. [211] proposed that taurine exerts its neuroprotective effects
by inhibiting glutamate-induced calcium influx through L-, P/Q-, N-type voltage-gated calcium
channels (VGCCs) and NMDA receptor calcium channels. They further suggested that taurine protects
neurons against glutamate excitotoxicity by opening chloride channels to prevent glutamate-induced
calcium influx, a mechanism that also has anti-apoptotic effects [212].
Hussy et al. [213] investigated agonist properties of taurine on glycine and GABAA receptors of
rat supraoptic magnocellular neurons. They found that responses to 1 mM taurine were blocked by
strychnine, but not by gabazine, and were not additive with glycine-induced currents, indicating that
glycine receptors were selectively activated. Glycine receptor activation opens Cl−-selective channels,
and the resulting hyperpolarization prevents the neuron from firing [214]; hence, the inhibitory
nature of glycine receptors. Bhattarai et al. [215] found that taurine activates different subtypes of
glycine receptors in preoptic hypothalamic area neurons. Moreover, 500 µM taurine activated only
glycine receptors, but 3 mM taurine activated both glycine and GABAA receptors. Since glycine
receptors regulate the excitability of motor and afferent sensory neurons, including pain fibers,
and participate in processing visual and auditory signals [214], agonism of glycine receptors by
taurine would be neurosuppressive.
Lastly, El Idrissi et al. [216] found that iv injection of taurine in rats caused hypotension and
tachycardia. Taurine significantly reduced systolic, diastolic, and mean arterial blood pressure in
freely moving rats. They also found that bath application of taurine to aortic rings caused vasodilation.
Thus, injection of exogenous taurine would serve to exacerbate the profound hypotension caused by
proteinaceous venom components. Are the quantities of taurine found in snake venoms sufficient to
exert a significant pharmacological effect in envenomated prey? At this point, we cannot say; however,
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its pharmacology is completely consistent with snake envenomation strategies and, if not, it is likely
that taurine quantities released from prey tissues are sufficient, after the manner of released adenosine.
2.6.6. Carnosine (β-Alanyl-L-histidine)
We were, at first, puzzled by the absence of histamine from most snake venoms and serotonin
from all of the venoms examined in this study (Figure 14, Supplementary Table S1), since many
venoms are known to provoke the release of these mediators of the immediate hypersensitivity
reaction [217–219]. However, low amounts of carnosine reduce blood pressure by acting upon
the sympathetic nerve innervating the kidneys, although high concentrations of carnosine had the
opposite effect [220,221]. Suppression of mean arterial pressure was blocked by administration of
the histamine H3 receptor antagonist, thioperamide [222], whereas augmentation of blood pressure
was provoked by high concentrations of carnosine, an effect blocked by the H1 receptor antagonist
diphenhydramine, These results exactly parallel the effects of different concentrations of histamine
itself, injected intracranially [223], suggesting that carnosine’s suppression of blood pressure is
primarily histaminergic. Other studies have suggested that carnosine’s antioxidant properties
may underlie its effects on blood pressure, but such effects are probably too slow to be relevant
to envenomation.
2.6.7. Lesser Amines and Alkaloids
Numerous studies have reported on the histamine-releasing capabilities of various snake
venoms [219,224–227], based upon their capacity to degranulate mast cells [228–230]; however, to the
best of our knowledge, histamine has been reported as an actual component of a snake venom only
once (Bitis gabonica) [231]. Recently, Mamede et al. [232] reported that the inflammatory reaction
caused by Bothrops moojeni venom is mediated by eicosanoids, histamine, nitric oxide, and bradykinin,
principally due to the action of phospholipases, metalloproteases, and serine proteases. We confirm
that histamine itself is present at potentially significant levels in Bothrops moojeni venom (Figure 14,
Supplementary Table S1).
N-Acetylhistamine occurs in the venoms of D. polylepis, C. cerastes, B. moojeni, and C. v. viridis at
low levels, with the highest titer occurring in Dendroaspis venom (not shown). When administered ip
to mice and rats, N-acetylhistamine was found to significantly increase tissue histamine levels, which
histidine, a precursor of histamine, did not [233].
The literature appears to be completely silent on the pharmacology of N-acetylputrescine,
a catabolite of putrescine. Triethylenediamine, trigonelline, 4-guanidinobutanamide, nicotinamide,
and triethanolamine are found at very low levels in many or all venoms (Figure 14). In most cases,
these may be essentially “housekeeping” levels in glandular tissues and, certainly, no convincing
case can be made for a role in envenomation, especially given that methyltyramine has hypertensive
effects [234]. 4-Guanidinobutanamide is an intermediate between arginine and 4-guanidinobutanoate,
which has been discussed above.
2.7. Amino Acids
Seventeen of the 20 proteogenic amino acids were found in venoms (Figure 16). Of the remaining
three, glycine would not have been detected because of the mass cutoff that was specified in the
mass spectrometer. The other two (asparagine, cysteine) were not present at detectable levels, in part
because chromatography on the HILIC column was not optimized for separation and detection of all
amino acids. In addition to the proteogenic amino acids, several non-proteogenic amino acids were
detected. These included N-acetyl-L-glutamate, ornithine, L-citrulline, and N6,N6,N6-trimethyl-L-lysine
(Figure 16). The latter serves as a precursor in carnitine synthesis [235]. Interestingly, D. polylepis
venom has much higher levels of both N6,N6,N6-trimethyl-L-lysine and proprionyl-L-carnitine.
N-Acetyl-L-glutamate is involved in arginine synthesis, but can also be deacetylated by amino acid
N-acetyltransferase [E.C. 2.3.1.1] to release glutamate. However, it was most abundant in B. multicinctus
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venom, which also had the highest level of arginine, suggesting that arginine synthesis may be
its primary function. Citrulline and ornithine are also both intermediates in the arginine cycle;
however, these two amino acids do not appear correlated with each other or with arginine (Figure 16).
Citrulline was highly abundant in O. hannah and C. cerastes venoms, while ornithine showed low to
modest concentrations in all venoms. We can offer no convincing explanations for the functions of
these two compounds.
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Figure 16. Free amino aci s found in venoms, listed in the order of abundance. L-arginine
serves as the precursor for nitric oxide; therefore, it potentially promotes hypotension. Proline
is a major constituent in hypotensive peptides, hence its abundance in Crotalus v. viridis venom.
Pyroglutamic acid (oxoproline) likewise blocks the N-terminus of crotaline and viperine hypotensive
peptides; hence its greater abundance in those venoms. Trimethyl-lysine is a precursor for carnitine
synthesis. Both trimethyl-lysine and proprionyl-L-carnitine are most concentrated in D. polylepis venom.
High concentrations of some other amino acids are more difficult to explain. Abundance is scaled on
the basis of the log10 of the total ion concentration. Taxonomic na es: Bmu, Bungarus multicinctus;
Dp, Dendro spis polyle is; Msp, Micrurus spixii; Ms1–3, Micrurus suri amensis, 3 individuals; Nk, Naja
kaouthia; Oh, Ophiophagus hannah; Cc, erastes cerastes; Ds, Daboia iamensis; Apl, Agkistrodon piscivorus
leucostoma; Bmo, Bothrops moojeni; Cdt, Crot lus durissus ter ificus; C v, Crotalus viridis viridis; Oo, Ovophis
okinavensis; Pe, Protobothrops elegans; Pf, Protobothrops flavoviridis.
The most abundant free amino acid in these venoms was L-arginine, which serves as a substrate for
nitric oxide synthase (E.C. 1.14.13.39) in the production of nitric oxide, a potent inducer of hypotension
(Figure 16). The next most abundant free amino acid is proline, which is a major constituent of
hypotensive peptides, including bradykinin-potentiating peptides and structurally related compounds
(see the subsequent section on peptides). Not surprisingly, Crotalus v. viridis presented the highest
proline concentration, followed by Ophiophagus hannah. Isoleucine was the third most abundant amino
acid, but this is could be a combination of b th isoleucine and leucine, since the mass spectrometer
cannot distinguish these.
We had expected t find elevat d titers of gl tamat and/or aspartate in D. polylepis v nom,
since the mambas employ an excitatory envenomation strategy [4], but the levels of these acidic amino
acids are not exceptional in any venom. In fact, our pooled sample of D. polylepis venom had the lowest
level of the four elapid venoms, exceeded by the levels in D. siamensis and several crotaline venoms.
Moreover, because kraits and cobras employ paralytic envenomation strategies, an excitatory role
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for these amino acids seems unlikely. On the other hand, a role for glycine might be possible, but as
mentioned, we did not gather data in that low a mass range.
2.8. Carbohydrates
Four mono- and disaccharides were identified in the 17 venoms examined. Consistent with reports
by Birrel et al. [236] and Zelanis et al. [237], all were N-acetylated forms (N-acetylneuraminic acid,
N-acetyl-D-galactosamine-4-sulfate, N-acetylglucosamine, bearing a C2H2O group, and N-acetyl-D
-lactosamine). N-Acetylneuraminic acid and N-acetylglucosamine are common terminating sugars
of asparagine-linked glycan moieties of venom glycoproteins [237–240]. N-acetylneuraminic acid
was relatively abundant in all venoms examined, while N-acetylglucosamine was found at higher
levels only in the venoms of C. cerastes, B. multicinctus, and C. d. terrificus (Figure 17). In the only such
report of which we are aware, Gowda and Davidson [241] found that Naja kaouthia venom contains
heavily glycosylated high-molecular-weight proteins bearing N-acetyl-lactosaminyl oligosaccharides.
Our results indicate that this sugar is more common in elapid and viperine venoms than in crotaline
venoms. We did not detect mannose (MW = 180.156), which is arguably the most abundant neutral
sugar reported in snake venom glycoprotein glycan moieties; however, as a neutral sugar, only very
large quantities of mannose could be detected under the LC-MS conditions we used.
Bmu Dp Msp Ms1 Ms2 Ms3 Nk Oh Cc Drs Apl Bmo Cdt Cvv Oo Pe Pf
26.  N-Acetylneuraminic Acid
258.  N-acetylglucosamine with C2H2O group
361.  N-Acetyl-D-lactosamine
585.  Gluconic acid 3
4
Elapidae
Bmo Pf Bmu Dp Msp Ms1 Ms2 Ms3 Nk Oh Cc Drs Apl Cdt Cvv Oo Pe
CrotalidaeViperidae
5
6
7
Figure 17. Relatively few mono- and disaccharides were found in these venoms and all were
in the N-acetylated form. N-Acetylneuraminic acid is a common terminating sugar in the
branched, asparagine-linked glycan moieties of snake venom glycoproteins. Mannose was not
recorded, but it could not have been detected under the conditions were used, except at very high
concentrations. Taxonomic names: Bmu, Bungarus multicinctus; Dp, Dendroaspis polylepis; Msp, Micrurus
spixii; Ms1–3, Micrurus surinamensis, 3 individuals; Nk, Naja kaouthia; Oh, Ophiophagus hannah;
Cc, Cerastes cerastes; Ds, Daboia siamensis; Apl, Agkistrodon piscivorus leucostoma; Bmo, Bothrops moojeni;
Cdt, Crotalus durissus terrificus; Cvv, Crotalus viridis viridis; Oo, Ovophis okinavensis; Pe, Protobothrops
elegans; Pf, Protobothrops flavoviridis.
2.9. Metabolite Biosynthetic Pathways
Aird et al. [173] found that the enzyme, spermine synthase, was strongly upregulated in the
venom glands of Protobothrops mucrosquamatus, leading to the discovery of polyamines as constituents
of snake venoms. However, that case was fortuitous. Generally speaking, we would expect to find
upregulation of enzymes in pathways leading to formation of the metabolites reported here, but by
virtue of being catalytic, enzymes have no stoichiometry. That is, a massive upregulation may not
be required to produce a considerable amount of some metabolites. Enhanced production of small
metabolites is normally expected to be more complicated than in the case of spermine synthesis, in that
not only should anabolic enzymes be upregulated, but catabolic enzymes may be downregulated or
inhibited. Furthermore, for enzymes that are bidirectional, there must be some way of removing and
sequestering the product so as to shift the equilibrium to facilitate additional metabolite formation.
2.10. Final Considerations about Organic Metabolites
Functional organic components of snake venoms may constitute a more complex case than their
proteinaceous counterparts. Venom proteins and peptides represent the endpoints of transcription and
translation of genes that are specifically upregulated for that purpose. In contrast, organic metabolites
that have been weaponized in venom glands represent intermediates in complex networks of metabolic
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enzymes. Most of these enzymatic reactions are reversible, and the direction of catalysis is governed
by relative concentrations of substrates and products. Moreover, the product of one reaction is the
substrate for another. How can any metabolite then become an endpoint? We believe that the only
possible answer is sequestration and transport out of venom gland cells into the lumen of the gland,
and we are now investigating this matter.
2.11. Peptides
In general, peptides tend to be more minor components of elapid venoms than of viperine
and crotaline venoms (Figure 18, Supplementary Table S2). Sequenced peptides ranged in mass
from 172–1716 Da. and included dipeptides, tripeptides, and oligopeptides of up to 13 residues.
However, it is apparent that the 71 peptides detected in this study include less abundant oligopeptides
of up to about 15 residues (Supplementary Tables S1 and S2). Moreover, we discovered three
glycosylated di- and tripeptides, present mostly in elapid venoms, and most abundant in venoms of
O. hannah and D. polylepis (Figure 18, Supplementary Table S2).
2.11.1. Dipeptides
To the best of our knowledge, only one dipeptide has been reported previously in snake venoms,
but we identified 13 in the 17 venoms surveyed. Lunow et al. [242] reported that dipeptides containing
an aliphatic amino acid in the P1 position and tryptophan in the P2 position are good inhibitors of
the C-domain of angiotensin-converting enzyme (ACE), which reduces blood pressure by degrading
hypertensive peptides [243,244]. None of the dipeptides we isolated possessed tryptophan in the P2
position, although one of the tripeptides did. Six oligopeptides had tryptophan in the P3 position
(Figure 18). Greene et al. [245] noted that the common characteristics of bradykinin-potentiating
peptides from Bothrops jararaca venom include an N-terminal pyroglutamate residue, a high percentage
of proline residues, with proline at the C-terminus. All of the dipeptides we found had either
pyroglutamate as the first residue or proline as the second.
Prolyl Dipeptides
Five prolyl dipeptides sequenced during this study included four aliphatic prolyl peptides,
Val–Pro, Ala–Pro, Gly–Pro, and Ile–Pro, as well as Pro–Pro (Figure 18, Supplementary Table S2).
Though it lacks an N-terminus blocked with pyroglutamate, valylproline is, reportedly, a slight
inhibitor of ACE (IC50 = 420 µM) [246]. More importantly, it inhibits the human peptide transporter,
hPepT2 [247], which is expressed in astrocytes, subependymal cells, ependymal cells and epithelial
cells of the choroid plexus [248]. hPepT2 is responsible for clearing di- and tripeptides, ACE inhibitors,
and other substances from the cerebrospinal fluid [249,250]. Thus, Val–Pro may prevent the clearance
of other venom hypotensive peptides, further deepening the hypotension induced by other venom
constituents. In the present study, Val–Pro was most abundant in C. v. viridis venom (Figure 18).
The literature appears entirely silent on the subject of Ile–Pro and Pro–Pro pharmacology.
However, given its structural and physicochemical similarity to Val–Pro, we hypothesize that Ile–Pro
also inhibits hPepT2. A tripeptide, AAP, from the venom of Deinagkistrodon acutus, has been reported
to inhibit platelet aggregation [251]. It may be that both Val–Pro and Ile–Pro share this function.
As mentioned above, we also found Ala–Pro. According to PubChem, “This dipeptide has not yet
been identified in human tissues or biofluids and so it is classified as an ‘Expected’ metabolite”
(https://pubchem.ncbi.nlm.nih.gov/compound/418040). Gly–Pro, like Val–Pro, was also tested for its
capacity to inhibit ACE, and yielded an even more tepid result (IC50 = 447 µM). There is one additional
possible pharmacological action of the aliphatic proline peptides. Hirota et al. [252] reported that in
addition to ACE inhibition, the tripeptides VPP and IPP also release NO from vascular endothelial cells,
inducing endothelium-dependent relaxation of isolated aortic rings. It remains to be seen whether
these dipeptides have similar activity.
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Figure 18. All venoms examined contained peptides. Those sequenced ranged from 172–1716 Da
(2–15 amino acids). Many of these were pyroglutamyl and/or prolyl peptides. Their pharmacologies
are largely unknown at this point. Taxonomic names: Bmu, Bungarus multicinctus; Dp, Dendroaspis
polylepis; Msp, Micrurus spixii; Ms1–3, Micrurus surinamensis, 3 individuals; Nk, Naja kaouthia;
Oh, Ophiophagus hannah; Cc, Cerastes cerastes; Ds, Daboia siamensis; Apl, Agkistrodon piscivorus leucostoma;
Bmo, Bothrops moojeni; Cdt, Crotalus durissus terrificus; Cvv, Crotalus viridis viridis; Oo, Ovophis okinavensis;
Pe, Protobothrops elegans; Pf, Protobothrops flavoviridis.
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Pyroglutamyl Dipeptides
A total of 8 pyroglutamyl dipeptides were identified in this study (pEE, pEG, pEH, pEK, pEN,
pEQ, pER, pES). pEK, which was reported in the venom of Bothrops moojeni by Menin et al. [253],
was more abundant in our samples of C. cerastes and P. elegans venoms than in B. moojeni venom
(Figure 18, Supplementary Table S2). Even though levels in other venoms were rather modest, this was
one of the few peptides that displayed roughly similar titers among all families of snakes. So far as we
are aware, nothing is known about the pharmacology of any of these dipeptides; however, they exhibit
distinctly taxon-specific distributions. pEH is quite abundant in D. polylepis venom, implying that it
may contribute to hypotension. Beyond that, it is most abundant in the three M. surinamensis venoms.
In the venoms we surveyed, pEE, the only member of this group with an acidic amino acid in the
second position, was most abundant in C. cerastes and P. elegans venoms (Figure 18). The remaining pE
dipeptides (pEG, pEK, pEN, pEQ, pER, and pES) were all most abundant in crotaline venoms and,
sometimes, also in viperine venoms.
pEG is striking for its lack of large charged, hydrophilic, or aliphatic residues. We can do little
more than speculate about its possible function. It is tempting to suggest that it might block glycine
receptors. This peptide is most abundant in P. elegans venom with ~10× lower concentrations in all
other venoms, except for the two rattlesnakes, which had substantially lower concentrations than all
other venoms (Figure 18). PubChem reports that the dipeptide, pyroglutamyl–valine, is essentially
insoluble in water. All venom pyroglutamyl dipeptides involve hydrophilic amino acids in the
second position.
2.11.2. Pyroglutamyl Tripeptides
Eleven venom tripeptides, displaying a wide range of concentrations, were sequenced in this
study (pEKW, pENW, pEWQ, pE(NH), pEKS, pEPQ, pEGE, pERI, pERP, pESN, and pEND, in order
of decreasing abundance) (Figure 18, Supplementary Table S2). Inadequate fragmentation prevented
us from confirming whether the fourth peptide has the sequence pENH or pEHN. Tripeptides
were first discovered in venoms more than 50 years ago. Kato et al. [254] found two tripeptides,
pEQW and pENW, in the venoms of Gloydius blomhoffii, Crotalus adamanteus, Bothrops jararaca,
and Protobothrops flavoviridis, which do not potentiate bradykinin, suggesting that they do not
inhibit angiotensin-converting enzyme (ACE). They found that Daboia russellii venom contained
only pENW, while Naja atra venom had neither. Francis and Kaiser [255] reported pENW and pEQW in
the venom of Bothrops asper at concentrations of 1 and 4.5 mM, respectively, and found that they
effectively inhibited two venom metalloproteases (80–90% inhibition) at peptide concentrations
below 1 mM. Lo [256] reported the tripeptides pEEW and pEDW from the venoms of the
pitvipers, Protobothrops mucrosquamatus and Trimeresurus gramineus, and pEKS was isolated from
Gloydius blomhoffii venom [257], but it appears that their pharmacologies are unknown. Lou et al. [258]
reported that the tripeptide, KNL, from the venom of Deinagkistrodon acutus, is able to inhibit a
fibrinogenolytic P-I metalloprotease in the same venom. We did not isolate this peptide, or anything
structurally similar.
pEKW
Yee et al. [259] reported that two tripeptides, pERW and pEKW, from Daboia russellii venom,
completely inhibited the gelatinolytic and fibrinogenolytic activities of the metalloproteases, RVV-X,
and Daborhagin, at a concentration of 5 mM. We did not isolate pERW; however, pEKW was
the most abundant peptide in any of these venoms, reaching its highest concentration in
C. cerastes, O. okinavensis, P. flavoviridis, P. elegans, B. moojeni, and D. polylepis venoms (Figure 18).
Wagstaff et al. [260] reported that the ≤10 kDa portions of Cerastes cerastes and Echis ocellatus venoms
were predominantly comprised of this tripeptide. Huang et al. [261] found three endogenous
tripeptides in the venom of Protobothrops mucrosquamatus (pEKW, pENW, and pEQW) that inhibited
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the activities of multiple metalloproteases in the venom. pEKW was also reported as a metalloprotease
inhibitor in Bothrops jararaca venom [262] and in Cerastes cerastes and Echis ocellatus venoms [260].
The observation of Lunow et al. [242] that dipeptides with tryptophan in the P2 position inhibit ACE,
may also be applicable to tripeptides that bear a C-terminal tryptophan.
pENW
This tripeptide was abundant in all pitviper venoms that we surveyed, and it even occurred at
modest concentrations in C. cerastes, B. multicinctus, and D. polylepis venoms (Figure 18). Sciani and
Pimenta [263] reported that this tripeptide is found as a module in 9% of all bradykinin-potentiating
peptides. Munekiyo and Mackessy [264] found it in ten rattlesnake venoms, and reported that it
inhibits and stabilizes several of the major metalloproteases in these venoms. Robeva et al. [265]
reported that both pENW and pEEW effectively inhibit hemorrhagic toxin e from the venom of
Crotalus atrox, and suggested the dual function of inhibiting venom metalloproteases during storage in
the venom gland. pENW has also been reported to inhibit platelet adhesion and clot retraction in a
dose-dependent manner [266], an activity consistent with envenomation strategy to render the blood
of prey incoagulable.
pEKS
This peptide was first reported from the venom of Agkistrodon (Gloydius) halys blomhoffii by
Okada et al. [257]. The authors offered no pharmacology, but speculated that this and other
tripeptides might simply be enzymatically released metabolites. Nearly 45 years later, it is apparent
that most abundant short peptides are functional venom constituents, and not metabolic accidents.
However, we are no closer to understanding the pharmacology of most of them. This peptide, with its
blocked N-terminus, its high pI, and two extremely hydrophilic C-terminal amino acids, is especially
intriguing. We suspect that the Lys and Ser residues make this peptide an inhibitor of some prey
enzyme, receptor, or ion channel.
pEPQ, pEGE, pERI, pERP, pE(NH), pESN, and pEND
An additional seven tripeptides, pEPQ, pEGE, pERI, pERP, pE(NH), pESN, and pEND, were found
in these venoms. As mentioned above, we were unable to determine the exact sequence of the peptide
pE(NH). However, at this point, it probably does not matter. We are unaware of any reports of
these tripeptides in the toxinological literature, much less pharmacological profiles for them. With its
C-terminal Pro–Arg sequence, pEPR resembles a shortened version of oligopeptides with 5 or 11
residues. Pyroglutamyl tripeptides may represent hypotensive peptides with only two modules,
following the proposal of Sciani and Pimenta [263].
2.11.3. Tetrapeptides
The present study also discovered eight tetrapeptides (pEGRP, pETAP, pETGG, pELPP, pEKAG,
pEEGT, pE(GA)Q, and TPPA) (Figure 18, Supplementary Table S2). Orosz et al. [267] reported
the µ-opioid receptor activity of synthetic tetra- and pentapeptides having amidated C-termini and
blocked N-termini; however, with several aromatic residues and no prolines, their peptides do not
resemble the peptides reported here. Except for the last of these tetrapeptides, all appear to be
previously unknown. Given their blocked N-termini and/or proline residues, they are likely to be
hypotensive in some fashion, though not necessarily ACE inhibitors.
The sequence TPPA is the N-terminal tetrapeptide of an 11-amino acid peptide originally
discovered in 1986 by Aird and Kaiser in the venom of Crotalus v. viridis (discussed below), and later
found in other pitviper venoms [268]. It is likely that the tetrapeptide is simply a degradation product
of the full-length peptide, since its distribution parallels those of the two 11-mer isoforms, but it could
conceivably have its own biological activity, after the manner of crotalphine and crotoxin [269,270].
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2.11.4. Longer Oligopeptides
Longer oligopeptides were about equally divided between those bearing an N-terminal
pyroglutamate residue and those bearing paired prolines in the second and third positions
(Supplementary Table S2). This latter motif protects the N-terminus from degradation by proline
peptidase. Both groups tend to be proline-rich at the C-terminus, as well. Motifs such as
-HIPP, -PIPP, -PPIPP, and even -PPP are typical (Supplementary Table S2). While many nominal
bradykinin-potentiating peptides (BPPs) have ACE inhibitory activity to one degree or another,
many have other activities as well and, in some cases, ACE inhibition is not the primary effect.
Gomes et al. [271] found that an N-terminal pyroglutamate residue and high proline content, even
with a C-terminal IPP motif, are insufficient to specify bradykinin-potentiating activity.
Ianzer et al. [272] investigated the mechanisms of action of BPP 7a and BPP 10c from
Bothrops jararaca venom. BPP 7a does not potentiate the effects of bradykinin, and is a weak inhibitor
of the ACE C site (40,000 nM). By contrast, BPP 10c is a potent bradykinin potentiator and a potent
blocker of the ACE C site (0.5 nM) [272], but both cause persistent hypotension. Silva et al. [273]
reported that, in the presence of a saturating concentration of captopril, originally modeled after a
Bothrops jararaca pentapeptide, BPP 10c, a decapeptide [274], maintained high renal concentrations for
over 3 h, confirming its affinity for some renal target and also showing that ACE was not its only target.
Camargo et al. [275] reported that a BPP from Bothrops jararaca venom activates argininosuccinate
synthetase, resulting in increased nitric oxide production.
2.11.5. Oligopeptides
Bradycardia promoted by BPPs is unrelated to their bradykinin-potentiating activities, since
bradykinin promotes tachycardia [276]. Some BPPs exhibit high bradykinin-potentiating activity
while causing little inhibition of ACE [277]. BPP-5a, from Bothrops jararaca venom, induces protracted
reductions in mean arterial pressure and heart rate, via a nitric oxide-dependent mechanism that does
not involve ACE inhibition [278]. Cardiovascular effects may be of central origin since Bj-PRO-10c is
able to cross the blood–brain barrier [273] and central injections, thereof, were able to reduce blood
pressure in spontaneously hypertensive rats [273,279]. As mentioned above, it accomplishes this by
activating arginosuccinate synthetase [275].
pEGRPR
This pentapeptide appears to have been unreported, so far as we have been able to determine.
It possesses the C-terminal Pro–Arg sequence noted above for a tripeptide, and for blomhotin
(Gloydius blomhoffii) [280].
pESKPGRSPPISP
This bradykinin-potentiating peptide has been reported repeatedly from Protobothrops and
Trimeresurus venoms [14,15,271,281]. Our sample of P. flavoviridis venom had a very high titer of
this peptide. Traces were possibly present in B. moojeni and C. cerastes venoms. Most other venoms
were essentially devoid of this constituent.
TPPAGPDVGPR
This peptide was first discovered by Aird and Kaiser in 1986 (unpublished), who used Edman
degradation to determine the sequences of various low-molecular-weight constituents in the venom of
Crotalus v. viridis. That venom also showed the highest concentration of this peptide in the venoms
examined in the present study (Figure 18). When investigating the BPP-CNP gene of Crotalus durissus
collilineatus, Higuchi et al. [282] encountered a slight variant of this sequence (TPPAGPDGGPR). As a
result, they also re-isolated the C. v. viridis peptide, confirming the Val residue in position 8, synthesized
the Cdc variant, and then subjected both peptides to exhaustive cardiovascular pharmacological
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testing. The genetic and chromatographic data were presented by Shigesada Higuchi at the 14th
World Congress of the International Society on Toxinology, held in Adelaide, Australia, in 2003
(Supplementary Table S1). Peptide synthesis and cardiovascular pharmacology studies in collaboration
with Saad Lahlou at Universidade Federal de Pernambuco were just being initiated.
Lahlou determined that in both conscious and anesthetized rats, bolus iv doses of the Cdc peptide
as large as 600 µg/kg had no discernible effect on mean arterial pressure or heart rate during the test
period. In captopril-pretreated rats, it also had no effect on either parameter and, in isolated, perfused
rat heart preparations, it caused no change in left ventricular systolic pressure [268]. The Cvv peptide
likewise induced no changes in mean arterial pressure or heart rate when administered to conscious or
anesthetized rats in bolus iv doses up to 600 µg/kg. However, in captopril-pretreated rats, bolus doses
of 30, 100, and 300 µg/kg precipitated statistically significant hypotension within 30 s, which persisted
throughout the recording period. From its pharmacology, it was clear that this 11-residue peptide does
not inhibit ACE, it does not release Arg from its C-terminus for production of NO, and it does not
inhibit aminopeptidase P. Instead, its sequence and its pharmacology suggested that it functions as an
analog of anaphylatoxin C3a [268]. Most recently, Wang et al. [283] reported that this peptide from
C. v. viridis inhibits smooth muscle contractility in guinea pig ileum, but potentiates it in rat stomach
fundus. They surmised that these contrary activities might come from binding to different receptors
(bradykinin-B2 receptors in guinea pig ileum and anaphylatoxin C3a receptors in rat stomach fundus.
Hayashi et al. submitted the BPP-CNP gene sequence from Crotalus durissus terrificus venom
(AAL09427.1) to NCBI in 2000, but did not publish it until seven years later [271]. However, they did
not specifically mention this peptide and may have been unaware of it, since it lacks an N-terminal
pyroglutamate residue and paired prolines at the C-terminus, signature characteristics of BPPs [263].
In January, 2005, Soares et al. [284] next published this peptide sequence in the sequence of the
BPP-CNP gene from Lachesis muta venom, although, like the aforementioned authors, they evidently
were not aware of its presence. Pahari et al. also [285] published this sequence from the venom
gland transcriptome of the desert massasauga (Sistrurus catenatus edwardsii) (B0VXV8.1), but did
not specifically mention it in the publication. Despite the fact that this obscure peptide had been
repeatedly and understandably overlooked by extremely capable investigators, following Higuchi’s
2003 presentation in Adelaide, in November, 2005, Graham et al. [286] reported the peptide in
venoms of Crotalus v. viridis, Lachesis muta, and Agkistrodon bilineatus, concluding that it was a
bradykinin-inhibitory peptide. Given the well-documented and manifestly hypotensive nature of
crotaline venoms and their peptidyl components [4,287–291], that makes no sense.
With its widespread distribution among pitvipers, and the fact that the Cvv peptide accounts for
approximately 1% of the crude venom by mass [268], this toxin is unquestionably synergistic, with one
or more of the BPPs in these venoms, which probably act at a variety of sites to produce coordinated
hypotension. Interestingly, the apparently inactive Cdc toxin is expressed at almost undetectable levels,
and may represent a defective toxin that is experiencing negative selection [292].
pEEWPPCHHIPP
This 11-residue peptide is evidently a BPP, given its blocked N-terminus and paired C-terminal
prolines. This sequence is novel, but it is similar to sequences reported previously in venoms of Lachesis
muta [284], Crotalus adamanteus [293], and Trimeresurus gramineus [281].
(QPGQ)RPPHVPP
This peptide, like the preceding one, is restricted to C. v. viridis venom (Figure 18). The sequence
of the C-terminal 7 residues is certain. So is the composition of the N-terminal four residues, but due to
a lack of subfragmentation, the N-terminus cannot be ordered. From the C-terminal sequence, this is
probably a BPP. It is also likely that the P2 residue is proline, which would protect the P1 residue,
for which the most likely candidate is glutamine, based on other peptide sequences. P3–P4 could then
be either Gln–Gly or Gly–Gln.
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pENWPAPK
This BPP is most similar to BPPs 7b (pENWPSPK) and 10e (pENWPSPKVPP) from Bothrops cotiara
venom [294]. Among our samples, this peptide was essentially restricted to Crotalus v. viridis venom
(Figure 18).
pETGG
This is an odd sequence in that while the N-terminus is protected, the remaining three residues
are small and/or hydrophilic, without a protective proline. We cannot even hazard a guess as to its
pharmacology, but we suspect that it may be pharmacologically different from anything reported
to date.
pEGRP
This is probably a BPP, given its blocked N-terminus and proline in the P4 position, flanked by
arginine. We are not aware that it has been reported previously.
RPPHP
This peptide appears to be a BPP fragment. It is identical to the middle portion of BPPs from
Bothrops jararaca (pEQRPPHPPIPPAP) and Bothrops fonsecai (pEARPPHPPIPPAP) venoms; however, it is
difficult to imagine an enzymatic mechanism that would cut it at the two points necessary. In addition,
in our 50 most abundant compounds, there was no evidence of a parent peptide from which it might
have been derived, and it was found only in our pooled sample of Agkistrodon p. leucostoma venom
(Figure 18). The paired prolines in positions 2 and 3, and the C-terminal proline, suggest that it may be
fully functional as a BPP.
pEKAG
Like pETGG above, this is a peculiar tetrapeptide sequence. Again, the N-terminus is blocked
and the Lys–Ala–Gly sequence is hydrophilic and unprotected with Pro, although this peptide is basic.
pELPP
Given its blocked N-terminus and proline-bearing C-terminus, this is probably a very
hydrophobic, hypotensive tetrapeptide, but if ACE is not its target, it is hard to say what might be.
EPAVGGCC
This peptide appeared in Protobothrops elegans venom at a very high concentration and, possibly,
in Dendroaspis polylepis venom at a low concentration. All other venoms were essentially negative
(Figure 18). A BLAST search of the NCBI database yielded no credible matches, so it is not a degradation
product of any known protein. With paired cysteines at the C-terminus, this does not appear to be
a hypotensive peptide, although it does have a proline in the second position. We cannot offer a
hypothetical explanation of its pharmacological role in envenomation, if it has one.
Final Considerations about Peptides
We did not detect any homologs of the poly-His–poly-Gly metalloprotease-inhibitory peptide
isolated from Echis ocellatus venom by Wagstaff et al. [260]. Overall, elapids appear to make far less use
of short peptides (Figure 18), although some peptides (QEW, pENW, pEK, pEKS) appear to be widely
distributed across most taxa. Crotalines generally appear to make the greatest use of peptides, although
some species do so much more than others. Crotalus v. viridis, P. elegans, and P. flavoviridis all have high
concentrations of 7–10 of the most abundant peptides. Crotalus d. terrificus, which specializes in crotoxin
homologs [295], makes much less use of them. Likewise, C. cerastes employs high concentrations of a
variety of peptides, while D. siamensis does not (Figure 18).
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2.12. Venom Similarities in Terms of Metabolite and Peptide Content
The 17 venoms examined differed greatly in complexity and composition. For instance,
Dendroaspis polylepis was the simplest venom in terms of its metabolite composition, owing to its
purine intensive strategy. Seven constituents, including four purines, accounted for over 60% of the
metabolites in the venom. Adenosine alone comprised 26% of all metabolites and adenine added
another 11.6% (Supplementary Table S3). Purines were generally important in elapid and viperine
venoms, but not in crotaline venoms (Supplementary Table S3) [12].
In Bothrops moojeni venom, 25 constituents comprised the top 60% (Supplementary Table S3).
In Ophiophagus hannah venom, the most major organic component was 4-guanidinobutyric acid,
which represented 17.5% of venom metabolites. It was also the major metabolite of Bungarus
multicinctus venom, in which it comprised 7.3%. It was the third most abundant compound in
Micrurus spixii venom, and also made the top 60% in two of three Micrurus surinamensis venoms, and in
both viper and four pitviper venoms (Supplementary Table S3).
Citric acid was the dominant component in seven viperid venoms and in that of Naja kaouthia,
evidently reflecting a greater need to inactivate venom metalloproteases in those venoms. Peptides
figured prominently in most crotaline venoms, comprising 48% or all metabolites in Ovophis okinavensis
venom. Peptides dominated Crotalus viridis and both Protobothrops venoms. They were also very
important in Cerastes cerastes venom, where pEKW was the major constituent; however, Daboia siamensis
adopts a largely non-peptidyl strategy. Choline was in the top 60% of all metabolites in nine venoms.
We used the factoextra package with the function fviz_cluster in R to analyze compositional
affinities among the 17 venoms studied, based upon the 100 most abundant metabolites. The results
were largely as anticipated, but there were some surprises. The three M. surinamensis venoms formed
a discrete cluster (Cluster 1) separate from everything else, both by virtue of being conspecific and
due to this coral snake’s specialization upon fish, especially weakly electric fish (e.g., Gymnotus carapo)
(Figure 19A,B). Cluster 3 comprised three Ophiophagus taxa, M. spixii, B. multicinctus, and O. hannah.
Of these, O. hannah showed the greatest affinity for Cluster 2 (Figure 19B), which included New World
crotalines and a large viperine, D. siamensis. This is most likely because of the king cobra’s predilection
for rodents and other small mammals. Cluster 2 also included N. kaouthia, an elapid that is something
of a dietary generalist, though adults feed largely on mammals. Within Cluster 2, C. d. terrificus
was well separated from other New World crotalines. Daboia siamensis shows the greatest affinity for
Ophiophagus elapids. Cluster 4 embraced Old World crotalines (Protobothrops sp., and Ovophis, plus
Cerastes cerastes. While belonging to Cluster 2, A. p. leucostoma fell squarely in the midst of Cluster
4 (Figure 19B), with which Cluster 2 is closely allied. This is reasonable in that both clusters consist
mainly of crotalines. Lastly, D. polylepis formed its own cluster (5), due largely to its high titers of
purine nucleosides and acetylcholine.
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Figure 19. Clustering of 17 venomous snake taxa according to identities and concentrations of the top 
100 small metabolites in their venoms. (A) Dendrogram of the 17 specimens based upon similarities 
in their small metabolites and peptides. (B) Cluster analysis. Owing to their conspecificity and their 
preferred fish diet, three specimens of Micrurus surinamensis cluster tightly, well separated from 
everything else (Cluster 1). Cluster 2 comprises New World pitvipers, except for the viperine, Daboia 
siamensis, and Naja kaouthia, which is something of a dietary generalist, adults of which feed mostly 
on rodents and other small mammals. Micrurus spixii, which feeds upon snakes and amphisbaenians, 
most resembles the Ophiophagus Asian taxon, Bungarus multicinctus, in terms of venom metabolites. 
Ophiophagus hannah preys upon both snakes and mammals, and also falls into Cluster 3, although in 
the dendrogram, it clusters with N. kaouthia, C. d. terrificus, and the two viperines. The reason for this 
apparent discrepancy is that in the cluster analysis, only the first two of three dimensions can be 
shown. Cluster 4 includes Asian pitvipers and Cerastes cerastes, which sits on the border of Cluster 2. 
Cluster 5 contains Dendroaspis polylepis alone, the venom small metabolome of which is as unusual as 
its proteome. Colors in the dendrogram (A) reflect colors in the cluster analysis (B). The R script used 
to generate the dendrogram and to perform the cluster analysis is provided in Supplementary File 1. 
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3.1. Venoms 
Lyophilized venoms were reconstituted to 250 µg/µL by dissolving them in ultrapure water. 
Seventeen venoms examined in this study represented the families Elapidae, Viperinae, and 
Crotalinae (Supplementary Table S4). 
Figure 19. Clustering of 17 venomous snake taxa according to identities and concentrations of the top
100 small metabolites n their venoms. (A) Dendrogram of the 17 spe ime s based upon similarities
in their small metabolites and peptides. (B) Cluster analysis. Owing to their conspecificity and
their preferred fish diet, three specimens of Micrurus surinamensis cluster tightly, well separated from
everything else (Cluster 1). Cluster 2 comprises New World pitvipers, except for the viperine, Daboia
siamensis, and Naja kaouthia, which is something of a dietary generalist, adults of which feed mostly
on rodents and other small m mmals. Micrurus spixii, which feeds upo s akes and amphisbaenians,
most resembles the Ophi phagus Asian tax n, Bu garus ulticinctus, in terms of venom metabolites.
Ophiophagus hannah preys upon both snakes and mammals, and also falls into Cluster 3, although in
the dendrogram, it clusters with N. kaouthia, C. d. terrificus, and the two viperines. The reason for
this apparent discrepancy is that in the cluster analysis, only the first two of three dimensions can be
shown. Cluster 4 includes Asian pitvipers and Cerastes cerastes, which sits on the border of Cluster 2.
Cluster 5 contains Dendroaspis polylepis alone, the venom small metabolome of which is as unusual as
its proteome. Col rs in the dendrogram (A) reflect colors in the cluster analysis (B). The R script used
to generate the dendrogram and to perform the cluster analysis is provided in Supplementary File 1.
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3. Materials and Methods
3.1. Venoms
Lyophilized venoms were reconstituted to 250 µg/µL by dissolving them in ultrapure water.
Seventeen venoms examined in this study represented the families Elapidae, Viperinae, and Crotalinae
(Supplementary Table S4).
3.2. Initial Sample Preparation Using Ultrafiltration
Methanol and acetonitrile were purchased from ThermoFisher Scientific, Waltham, MA, USA,
and HEPES and PIPES were obtained from Dojindo, Tokyo, Japan. Centrifugal filters were
manufactured by Pall Corp., New York, NY, USA.
For each venom, 4 µL of a solution 250 µg/µL (~1 mg) was dissolved in 46 µL of ultrapure water.
This solution was immediately mixed with 200 µL of methanol/water to give a final concentration of
50% methanol containing 100 nM HEPES/PIPES. This mixture was transferred to a 10 kDa centrifugal
filtration device at 4 ◦C, and was centrifuged at 13,000 rpm for 10 min. Flow-through amounted
to ~230 µL, and was evaporated to dryness. Extracted metabolites were resuspended in 40 µL of
50% acetonitrile/water. However, after the initial experiments were completed, we decided to add
several other venoms to the study. The newly added venoms proved to be heavily contaminated with
polyethylene glycols. After many experiments to isolate the source of contamination, we discovered
that a new batch of Pall filters was responsible. Once the source of the problem was identified,
all experiments had to be repeated with a different batch of filters from the same manufacturer.
The problem did not recur. However, we now prewash all filters with 400 µL of ultrapure water to
wash out contaminants.
Proteomic studies have greatly benefited from the use of molecular cutoff centrifugal filters to
reduce sample handling time when buffer exchange is required. Filtration is much faster than with
traditional dialysis methods, and sample loss is reduced. Use of these filters allows removal of small
molecules from samples, retaining larger molecules on the filter. In a reversal of the usual procedures,
we used centrifugal filtration to deproteinate the flow through so as to collect small peptides and
metabolites for MS analysis.
Metabolites and peptides collected using methanol extraction all have high polarities,
making them difficult to retain on the traditionally used reverse phase columns. In our experience,
HILIC columns comprised of zwitterionic materials, have a much broader separation spectrum for
mildly to highly polar compounds.
3.3. Mass Spectrometry
Samples (3 µL) representing the metabolite and peptide equivalent of 69 µg of each crude venom,
were injected into a Thermo Q-Exactive HF mass spectrometer (ThermoFisher Scientific, Waltham, MA,
USA) using a Dionex UHPLC Ultimate 3000 liquid chromatograph (Dionex, Sunnyvale, CA, USA).
Both hydrophobic interaction and reverse phase chromatography were used to separate metabolites
prior to their injection into the mass spectrometer.
3.3.1. Hydrophobic Interaction Chromatography
A SeQuant ZIC-pHILIC HPLC 2.1 × 150 mm column (Merck Millipore, Burlington, MA, USA)
was used for separation, flow rate 250 µL/min, using acetonitrile as solvent A and 10 mM ammonium
carbonate, 0.2% ammonium hydroxide (pH 9.4) as solvent B. Separation was done in HILIC mode,
with a linear gradient from 20% to 80% solvent B in 15 min, followed by a wash for 20 min with 20%
acetonitrile, 0.5 M ammonium carbonate in water (solvent C) and, finally, column re-equilibration
under starting conditions for 15 min [296].
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3.3.2. Reverse Phase Chromatography
A Waters ACQUITY CSH C18 2.1 × 150 mm column (Waters Corporation, Milford, MA, USA)
was used for separation, flow rate 200 µL/min, using 0.1% formic acid in water as solvent A, and 0.1%
formic acid in acetonitrile as solvent B. Separation was done in reverse phase, with a linear gradient
from 1% to 100% solvent B in 20 min, followed by a 5 min wash with 100% solvent B, and column
re-equilibration at 1% B for 10 min.
3.3.3. Mass Spectrometry Parameters
The mass spectrometer was operated in both positive and negative ion modes, acquiring one
spectrum at MS1 level and MS2 of the 10 most intense peaks in positive mode, switching to negative
mode and collecting same spectra. Mass spec settings were as follows, mass range from 70 to 1000
m/z, mass resolution 60,000 with Automatic Gain Control at 1 × 106, maximum injection time 30 ms,
profile mode for MS1 level. Fixed starting mass at 50 m/z, mass resolution 15,000, with AGC at 1 × 105,
maximum injection time 50 ms, top 10 most intense ions for MS2 level. Ionization settings were sheath
gas flow rate 40, auxiliary gas flow rate 5, spray voltage 3 kV (both modes), capillary temperature
320 ◦C, and S-lens RF level 60. Retention time, alignment, and peak intensity normalization among
samples were performed using 100 nM HEPES/PIPES as internal standards.
3.3.4. Identification and Quantification of Metabolites and Peptides
Compounds were identified using an in-house database of >600 commercial standards, analyzed
using the same conditions as in this study. Based upon retention time, precursor ion mass in positive
and/or negative mode, and MS2 fragmentation of standards we assigned identifications. Compounds
not included in this database were resolved using precursor ion mass and MS2 fragmentation with
Compound Discoverer 2.0 (ThermoFisher Scientific, Waltham, MA, USA, 2015) and MzMine 2.3
software [297] with the NIST, Pubchem, Human Metabolome, and KEGG chemical database libraries.
In case of ambiguities, in silico fragmentation of suspected compounds or their structural components
was performed using the MetFrag Web Tool (https://msbi.ipb-halle.de/MetFragBeta/). Compound
names or tentative identifications reflect our best understanding of these structures based upon our
interpretations of their fragmentation spectra. Normalization of peak areas was done in Compound
Discoverer 2.0.
With regard to peptide sequences, all spectra annotated as peptides were analyzed manually and
confirmed by isotopic simulation of parental ions, and their fragment ions using 10 ppm deviation
tolerance for a high level of confidence. PEAKs Studio software, version 7 (Bioinformatics Solutions
Inc., Waterloo, ON, Canada) was used for de novo sequencing to confirm manual sequence annotation.
We are working to create a fragmentation library of these very small venom peptides, which are not
available in public fragmentation libraries. This we intend to publish separately when it reaches a
greater degree of completeness.
3.3.5. Clustering and Hierarchical Classification
We used the factoextra package in R with the function fviz_cluster to assess affinities of the 17
venoms based upon the identities and quantities of small metabolites and peptides (https://CRAN.R-
project.org/package=factoextra). Statistical analysis of metabolite lists obtained for all samples was
performed with R packages, initial analysis included almost 900 metabolites, but just the 50 most
abundant ones were used for cluster analysis. The script for this analysis is provided in Supplementary
File 1.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/10/10/392/
s1, Table S1: Metabolites detected in 17 snake venoms, Table S2: Most abundant venom constituents in each
venom. All venoms examined contained peptides, ranging in length from 2–15 residues. Many were pyroglutamyl
peptides and many others contained one or multiple proline residues. Three were glycosylated dipeptides.
Peptide sequences or characterizations, masses, elution times, probable amino acid count, and species with the
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highest concentration of each are provided. Some sequences contain amino acid codes in parentheses, e.g., #11.
This indicates that the composition within the parentheses is confirmed, but the exact sequence is not known.
Table S3: Comparisons of organic constituent complexity in 17 snake venoms. Organic compounds are listed in
decreasing order of abundance for each taxon or individual, showing their relative importance and illustrating
differences between samples. In D. polylepis venom, seven compounds comprised over 60% of all small organic
constituents, whereas in B. moojeni venom, 25 compounds comprised this portion. Table S4: Venom suppliers and
origins of samples, where known. Data for specimens employed in this study. Supplementary File 1: The R script
used to create the dendrogram and to perform the cluster analysis, depicted in Figure 19.
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